[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 39 of about 39
1. Bangaru ML, Woodliff J, Raff H, Kansra S: Growth suppression of mouse pituitary corticotroph tumor AtT20 cells by curcumin: a model for treating Cushing's disease. PLoS One; 2010;5(4):e9893
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Growth suppression of mouse pituitary corticotroph tumor AtT20 cells by curcumin: a model for treating Cushing's disease.
  • BACKGROUND: Pituitary corticotroph tumors secrete excess adrenocorticotrophic hormone (ACTH) resulting in Cushing's disease (CD).
  • Standard treatment includes surgery and, if not successful, radiotherapy, both of which have undesirable side effects and frequent recurrence of the tumor.
  • Pharmacotherapy using PPARgamma agonists, dopamine receptor agonists, retinoic acid or somatostatin analogs is still experimental.
  • Curcumin, a commonly used food additive in South Asian cooking, has potent growth inhibitory effects on cell proliferation.
  • Our laboratory recently demonstrated that curcumin inhibited growth and induced apoptosis in prolactin- and growth hormone-producing tumor cells.
  • Subsequently, Schaaf et.al. confirmed our findings and also showed the in vivo effectiveness of curcumin to suppress pituitary tumorigenesis.
  • PRINCIPAL FINDINGS: Using the mouse corticotroph tumor cells, AtT20 cells, we report that curcumin had a robust, irreversible inhibitory effect on cell proliferation and clonogenic property.
  • The curcumin-induced growth inhibition was accompanied by decreased NFkappaB activity.
  • CONCLUSION: The ability of curcumin to inhibit NFkappaB and induce apoptosis in pituitary corticotroph tumor cells leads us to propose developing it as a novel therapeutic agent for the treatment of CD.
  • [MeSH-major] ACTH-Secreting Pituitary Adenoma / drug therapy. Cell Proliferation / drug effects. Curcumin / pharmacology. Pituitary ACTH Hypersecretion / drug therapy
  • [MeSH-minor] Adrenocorticotropic Hormone / secretion. Animals. Antineoplastic Agents. Apoptosis / drug effects. Cell Line, Tumor. Dose-Response Relationship, Drug. Mice. NF-kappa B / antagonists & inhibitors

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CURCUMIN .
  • Hazardous Substances Data Bank. Corticotropin .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Synapse. 2000 Mar 1;35(3):228-33 [10657030.001]
  • [Cites] Curr Opin Oncol. 2000 Nov;12(6):543-9 [11085453.001]
  • [Cites] Clin Endocrinol (Oxf). 2001 Feb;54(2):183-8 [11207632.001]
  • [Cites] J Clin Invest. 2001 Oct;108(8):1123-31 [11602619.001]
  • [Cites] Anticancer Res. 2001 Jul-Aug;21(4B):2895-900 [11712783.001]
  • [Cites] Carcinogenesis. 2002 Jan;23(1):143-50 [11756235.001]
  • [Cites] J Biol Chem. 2002 Mar 8;277(10):8329-37 [11756417.001]
  • [Cites] Prostate. 2002 Aug 1;52(3):183-200 [12111695.001]
  • [Cites] Nat Med. 2002 Nov;8(11):1281-7 [12379847.001]
  • [Cites] Tumori. 2003 Jan-Feb;89(1):54-9 [12729363.001]
  • [Cites] Mol Cancer Ther. 2004 Sep;3(9):1101-8 [15367704.001]
  • [Cites] Lancet. 1982 Sep 18;2(8299):646-9 [6125785.001]
  • [Cites] J Cell Physiol. 1992 May;151(2):326-36 [1572907.001]
  • [Cites] J Biol Chem. 1995 Oct 20;270(42):24995-5000 [7559628.001]
  • [Cites] Oncogene. 1996 Aug 1;13(3):609-16 [8760302.001]
  • [Cites] J Clin Invest. 1997 Dec 15;100(12):2952-60 [9399940.001]
  • [Cites] J Clin Invest. 1997 Dec 15;100(12):2961-9 [9399941.001]
  • [Cites] J Invest Dermatol. 1998 Oct;111(4):656-61 [9764849.001]
  • [Cites] Clin Cancer Res. 1999 Jan;5(1):119-27 [9918209.001]
  • [Cites] Biochem Pharmacol. 1999 Oct 1;58(7):1167-72 [10484074.001]
  • [Cites] Carcinogenesis. 2004 Nov;25(11):2183-9 [15256484.001]
  • [Cites] J Endocrinol Invest. 2004 Dec;27(11):1055-9 [15754738.001]
  • [Cites] Mol Cell Endocrinol. 2005 Jul 15;239(1-2):27-36 [15950373.001]
  • [Cites] Biochem Pharmacol. 2005 Sep 1;70(5):700-13 [16023083.001]
  • [Cites] Ann N Y Acad Sci. 2005 Nov;1056:206-17 [16387689.001]
  • [Cites] Mol Cancer Ther. 2006 Oct;5(10):2563-71 [17041101.001]
  • [Cites] Mol Endocrinol. 2006 Nov;20(11):2976-86 [16873443.001]
  • [Cites] Mol Cancer Ther. 2007 Mar;6(3):1022-30 [17363495.001]
  • [Cites] J Pharmacol Exp Ther. 2007 May;321(2):616-25 [17289836.001]
  • [Cites] Cell. 2007 Sep 7;130(5):769-74 [17803898.001]
  • [Cites] Endocrinology. 2008 Aug;149(8):4158-67 [18450960.001]
  • [Cites] J Clin Endocrinol Metab. 2009 Jan;94(1):115-22 [18957506.001]
  • [Cites] Neuroendocrinology. 2009;90(3):292-300 [19684383.001]
  • [Cites] Endocr Relat Cancer. 2009 Dec;16(4):1339-50 [19726538.001]
  • [ErratumIn] PLoS One. 2010;5(4). doi:10.1371/annotation/38a101d6-a1f2-4a74-ab63-bc5c61e5f62b
  • (PMID = 20405005.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / NF-kappa B; 9002-60-2 / Adrenocorticotropic Hormone; IT942ZTH98 / Curcumin
  • [Other-IDs] NLM/ PMC2854133
  •  go-up   go-down


2. Boulis NM, Noordmans AJ, Barkan A, Hassing J, Chandler WF: Somatotropinoma infarction during octreotide therapy leading to bilateral cavernous sinus syndrome. Pituitary; 2000 Nov;3(3):185-8
MedlinePlus Health Information. consumer health - Pituitary Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Somatotropinoma infarction during octreotide therapy leading to bilateral cavernous sinus syndrome.
  • The cyclic somatostatin analog, octreotide, forms the mainstay of medical treatment for acromegaly.
  • In addition to lowering circulating growth hormone levels and shrinking tumor size, octreotide may provide symptomatic relief of headaches associated with growth hormone secreting tumors.
  • The majority of reported complications of octreotide therapy are gastrointestinal and metabolic.
  • The present case illustrates the development of acute bilateral cavernous sinus syndrome with loss of eye movement bilaterally during octreotide therapy.
  • Serial MRI examination suggest tumor infarction as the etiology.
  • The symptoms resolved over 2 months as the tumor shrunk in size and growth hormone was dramatically reduced.
  • [MeSH-major] Cavernous Sinus. Cerebral Infarction / chemically induced. Cranial Nerve Diseases / chemically induced. Human Growth Hormone / secretion. Octreotide / adverse effects. Ophthalmoplegia / chemically induced. Pituitary Neoplasms / chemically induced. Pituitary Neoplasms / secretion
  • [MeSH-minor] Abducens Nerve / drug effects. Child. Female. Humans. Magnetic Resonance Imaging. Oculomotor Nerve / drug effects. Syndrome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Metabolism. 1992 Sep;41(9 Suppl 2):22-33 [1355588.001]
  • [Cites] Neurol Med Chir (Tokyo). 1990 May;30(5):350-3 [1699153.001]
  • [Cites] Biol Psychiatry. 1989 May;26(1):97-101 [2541810.001]
  • [Cites] Scand J Gastroenterol. 1998 Dec;33(12):1303-9 [9930395.001]
  • [Cites] Cephalalgia. 1997 Feb;17(1):27-30 [9051332.001]
  • [Cites] N Engl J Med. 1996 Jan 25;334(4):246-54 [8532003.001]
  • [Cites] J Endocrinol. 1997 Oct;155 Suppl 1:S53-5 [9389996.001]
  • [Cites] South Med J. 1988 May;81(5):660-3 [3368818.001]
  • [Cites] Cephalalgia. 1994 Aug;14(4):303-4 [7954762.001]
  • [Cites] J Surg Res. 1993 Oct;55(4):446-50 [7692142.001]
  • [Cites] Endocr Rev. 1988 Nov;9(4):417-36 [2905987.001]
  • [Cites] J Neurosurg. 1983 Oct;59(4):677-9 [6886789.001]
  • [Cites] Pain. 1991 Dec;47(3):341-4 [1664509.001]
  • [Cites] Lab Invest. 1999 Aug;79(8):935-44 [10462031.001]
  • [Cites] N Engl J Med. 1995 Aug 31;333(9):555-60 [7623904.001]
  • [Cites] Lancet. 1993 Jul 31;342(8866):301 [8101320.001]
  • [Cites] Am J Med. 1994 Nov;97(5):468-73 [7977436.001]
  • [Cites] Neurosurgery. 1988 Sep;23(3):395-8 [3226523.001]
  • [Cites] J Endocrinol Invest. 1999 Oct;22(9):698-700 [10595834.001]
  • [Cites] Med Clin (Barc). 1989 Oct 28;93(13):501-2 [2622243.001]
  • [Cites] J Clin Endocrinol Metab. 1988 Nov;67(5):1040-8 [2903168.001]
  • [Cites] Arch Intern Med. 1989 Jun;149(6):1443-5 [2730266.001]
  • (PMID = 11383484.001).
  • [ISSN] 1386-341X
  • [Journal-full-title] Pituitary
  • [ISO-abbreviation] Pituitary
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 12629-01-5 / Human Growth Hormone; RWM8CCW8GP / Octreotide
  •  go-up   go-down


3. Theodoropoulou M, Tichomirowa MA, Sievers C, Yassouridis A, Arzberger T, Hougrand O, Deprez M, Daly AF, Petrossians P, Pagotto U, Beckers A, Stalla GK: Tumor ZAC1 expression is associated with the response to somatostatin analog therapy in patients with acromegaly. Int J Cancer; 2009 Nov 1;125(9):2122-6
ORBi (University of Liege). Free full Text at ORBi .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor ZAC1 expression is associated with the response to somatostatin analog therapy in patients with acromegaly.
  • Somatostatin analogs (SSA) with their potent antisecretory and antiproliferative effects are the main medical treatment option for patients with neuroendocrine tumors, such as gastroenteropancreatic and acromegaly-associated growth hormone secreting pituitary tumors.
  • Although a good portion of acromegalic patients gets normalized after SSA treatment, strict hormonal control is not achieved in a sizeable proportion of these patients.
  • The reasons for this incomplete response to SSA treatment are unclear.
  • We have found that the tumor suppressor ZAC1 (LOT1/PLAGL1) is essential for the antiproliferative effect of SSA in pituitary tumor cells.
  • The aim of the present retrospective cohort study was to determine whether ZAC1 immunoreactivity in archival somatotrophinoma tissue derived from 45 patients with acromegaly routinely pretreated with SSA before surgery, was associated with response to SSA (normalization of GH, IGF-I and presence of tumor shrinkage).
  • A significant positive correlation was found between strong ZAC1 immunoreactivity and IGF-I normalization and presence of tumor shrinkage after SSA treatment, which was not affected by age at diagnosis, gender or duration of SSA treatment.
  • These in vivo data combined with the antiproliferative properties of ZAC1/Zac1 provide evidence of a mechanistic role for this transcription factor on SSA induced tumor shrinkage and hormone normalization.
  • [MeSH-major] Acromegaly / drug therapy. Cell Cycle Proteins / analysis. Octreotide / therapeutic use. Peptides, Cyclic / therapeutic use. Pituitary Neoplasms / drug therapy. Somatostatin / analogs & derivatives. Transcription Factors / analysis. Tumor Suppressor Proteins / analysis
  • [MeSH-minor] Adolescent. Adult. Aged. Cohort Studies. Female. Human Growth Hormone / blood. Humans. Insulin-Like Growth Factor I / analysis. Male. Middle Aged. Retrospective Studies

  • Genetic Alliance. consumer health - Acromegaly.
  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2009 UICC.
  • (PMID = 19637311.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cell Cycle Proteins; 0 / PLAGL1 protein, human; 0 / Peptides, Cyclic; 0 / Transcription Factors; 0 / Tumor Suppressor Proteins; 118992-92-0 / lanreotide; 12629-01-5 / Human Growth Hormone; 51110-01-1 / Somatostatin; 67763-96-6 / Insulin-Like Growth Factor I; RWM8CCW8GP / Octreotide
  •  go-up   go-down


Advertisement
4. Tajima T, Tsubaki J, Ishizu K, Jo W, Ishi N, Fujieda K: Case study of a 15-year-old boy with McCune-Albright syndrome combined with pituitary gigantism: effect of octreotide-long acting release (LAR) and cabergoline therapy. Endocr J; 2008 Jul;55(3):595-9
Genetic Alliance. consumer health - McCune Albright syndrome.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Case study of a 15-year-old boy with McCune-Albright syndrome combined with pituitary gigantism: effect of octreotide-long acting release (LAR) and cabergoline therapy.
  • The use of octreotide-LAR and cabergoline therapy has shown great promise in adults with acromegaly; however, the experience in pediatric patients has rarely been reported.
  • We described a clinical course of a 15-year-old boy of McCune-Albright syndrome (MAS) with pituitary gigantism.
  • At the age of 8 years, a growth hormone (GH) and prolactin (PRL) producing pituitary adenoma was diagnosed at our hospital.
  • The tumor was partially resected, and GNAS1 gene mutation (R201C) was identified in affected tissues.
  • During therapy with octreotide, IGF-1 and GH levels could not be suppressed and the patient frequently complained of nausea from octreotide treatment.
  • Therefore, the therapy was changed to monthly injections of octreotide-LAR at the age of 12.3 years and was partially effective.
  • This case demonstrated the difficulty of treating pituitary gigantism due to MAS.
  • [MeSH-major] Ergolines / administration & dosage. Fibrous Dysplasia, Polyostotic / complications. Fibrous Dysplasia, Polyostotic / drug therapy. Gigantism / complications. Gigantism / drug therapy. Octreotide / administration & dosage

  • Genetic Alliance. consumer health - Gigantism.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18445999.001).
  • [ISSN] 1348-4540
  • [Journal-full-title] Endocrine journal
  • [ISO-abbreviation] Endocr. J.
  • [Language] eng
  • [Publication-type] Case Reports; Evaluation Studies; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Delayed-Action Preparations; 0 / Ergolines; LL60K9J05T / cabergoline; RWM8CCW8GP / Octreotide
  •  go-up   go-down


5. Biermasz NR, Smit JW, Pereira AM, Frölich M, Romijn JA, Roelfsema F: Acromegaly caused by growth hormone-releasing hormone-producing tumors: long-term observational studies in three patients. Pituitary; 2007;10(3):237-49
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acromegaly caused by growth hormone-releasing hormone-producing tumors: long-term observational studies in three patients.
  • We report on three newly diagnosed patients with extracranial ectopic GHRH-associated acromegaly with long-term follow-up after surgery of the primary tumor.
  • One patient with a pancreatic tumor and two parathyroid adenomas was the index case of a large kindred of MEN-I syndrome.
  • During medical treatment basal GH secretion remained (slightly) elevated and secretory regularity was decreased in 24 h blood sampling studies.
  • We did not observe development of tachyphylaxis towards the drug or radiological evidence of (growing) metastases.
  • We propose life-long suppressive therapy with somatostatin analogs in cases with persisting elevated serum GHRH concentrations after removal of the primary tumor.
  • [MeSH-major] Acromegaly / etiology. Adenoma / secretion. Carcinoid Tumor / secretion. Human Growth Hormone / secretion. Lung Neoplasms / secretion. Pancreatic Neoplasms / secretion. Paraneoplastic Endocrine Syndromes / metabolism. Parathyroid Neoplasms / secretion
  • [MeSH-minor] Adult. Entropy. Female. Hormones / blood. Humans. Longitudinal Studies. Magnetic Resonance Imaging. Male. Middle Aged. Octreotide. Pituitary Gland / pathology. Positron-Emission Tomography. Tomography, X-Ray Computed. Treatment Outcome

  • Genetic Alliance. consumer health - Acromegaly.
  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 1987 Nov;84(21):7686-90 [2823271.001]
  • [Cites] J Clin Endocrinol Metab. 1992 Jul;75(1):281-4 [1619020.001]
  • [Cites] Endocr Rev. 1988 Aug;9(3):357-73 [3145190.001]
  • [Cites] J Clin Endocrinol Metab. 1989 Feb;68(2):499-504 [2493033.001]
  • [Cites] Endocrinology. 1989 Nov;125(5):2710-8 [2507296.001]
  • [Cites] Proc Soc Exp Biol Med. 1990 Mar;193(3):232-5 [2106141.001]
  • [Cites] Clin Endocrinol (Oxf). 1990 Mar;32(3):315-21 [2111746.001]
  • [Cites] Endocrinology. 1990 Nov;127(5):2149-56 [2226307.001]
  • [Cites] J Clin Endocrinol Metab. 1991 Sep;73(3):569-76 [1908480.001]
  • [Cites] Endocrinol Metab Clin North Am. 1992 Sep;21(3):575-95 [1521513.001]
  • [Cites] Endocr Rev. 1992 Aug;13(3):476-98 [1425484.001]
  • [Cites] J Endocrinol Invest. 1993 Jan;16(1):69-81 [8445159.001]
  • [Cites] Am J Physiol. 1994 Apr;266(4 Pt 2):H1643-56 [8184944.001]
  • [Cites] J Clin Invest. 1994 Sep;94(3):1277-88 [8083369.001]
  • [Cites] Eur J Endocrinol. 1995 Sep;133(3):320-4 [7581949.001]
  • [Cites] J Clin Endocrinol Metab. 1996 Oct;81(10):3746-53 [8855833.001]
  • [Cites] J Clin Endocrinol Metab. 1997 Feb;82(2):634-7 [9024267.001]
  • [Cites] Neurosurgery. 1997 Mar;40(3):611-4; discussion 614-5 [9055303.001]
  • [Cites] Eur J Endocrinol. 1997 Apr;136(4):394-400 [9150699.001]
  • [Cites] Clin Endocrinol (Oxf). 1997 Aug;47(2):123-35 [9302383.001]
  • [Cites] J Clin Endocrinol Metab. 1998 Feb;83(2):688-92 [9467594.001]
  • [Cites] Eur J Endocrinol. 1998 Feb;138(2):164-9 [9506860.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Dec 21;96(26):14894-8 [10611309.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Feb;86(2):700-12 [11158034.001]
  • [Cites] Am J Physiol Regul Integr Comp Physiol. 2001 Mar;280(3):R721-9 [11171650.001]
  • [Cites] Arch Intern Med. 2001 Apr 9;161(7):1010-1 [11295968.001]
  • [Cites] J Clin Endocrinol Metab. 2001 May;86(5):2227-30 [11344231.001]
  • [Cites] Clin Endocrinol (Oxf). 2001 Jul;55(1):135-40 [11453963.001]
  • [Cites] Endocrinology. 2001 Sep;142(9):3764-73 [11517152.001]
  • [Cites] Am J Physiol Regul Integr Comp Physiol. 2001 Dec;281(6):R1975-85 [11705784.001]
  • [Cites] Ann Oncol. 2001;12 Suppl 2:S89-94 [11762359.001]
  • [Cites] Neurosurgery. 2002 Jun;50(6):1356-9; discussion 1360 [12015856.001]
  • [Cites] Exp Clin Endocrinol Diabetes. 2002 Jun;110(4):188-92 [12058343.001]
  • [Cites] Clin Endocrinol (Oxf). 2002 Jul;57(1):131-4 [12100081.001]
  • [Cites] Eur J Endocrinol. 2002 Sep;147(3):381-6 [12213676.001]
  • [Cites] Ann Endocrinol (Paris). 2002 Dec;63(6 Pt 1):536-9 [12527856.001]
  • [Cites] J Endocrinol Invest. 2003 Feb;26(2):163-9 [12739745.001]
  • [Cites] Am J Physiol Endocrinol Metab. 2004 Jan;286(1):E25-30 [14506078.001]
  • [Cites] J Thorac Cardiovasc Surg. 2004 Oct;128(4):631-2 [15457172.001]
  • [Cites] J Clin Endocrinol Metab. 1984 May;58(5):796-803 [6423659.001]
  • [Cites] Br Med J (Clin Res Ed). 1984 Aug 25;289(6443):453-5 [6432140.001]
  • [Cites] J Clin Endocrinol Metab. 1984 Nov;59(5):846-9 [6434585.001]
  • [Cites] Cancer. 1984 Nov 15;54(10):2097-108 [6435852.001]
  • [Cites] J Clin Invest. 1985 May;75(5):1584-90 [2860126.001]
  • [Cites] Presse Med. 1985 Dec 7;14(42):2129-34 [2868453.001]
  • [Cites] Am J Physiol. 1986 Apr;250(4 Pt 1):E486-93 [3008572.001]
  • [Cites] Acta Endocrinol (Copenh). 1986 Sep;113(1):23-8 [2876570.001]
  • [Cites] Am J Surg Pathol. 1987 Oct;11(10):810-9 [2889383.001]
  • [Cites] Clin Endocrinol (Oxf). 1998 Feb;48(2):243-50 [9579239.001]
  • [Cites] J Clin Endocrinol Metab. 1998 Sep;83(9):3104-9 [9745411.001]
  • [Cites] J Clin Endocrinol Metab. 1999 Feb;84(2):582-9 [10022420.001]
  • [Cites] Eur J Endocrinol. 1999 Mar;140(3):192-200 [10216513.001]
  • [Cites] J Clin Endocrinol Metab. 1999 May;84(5):1761-2 [10323416.001]
  • [Cites] J Clin Endocrinol Metab. 1999 Sep;84(9):3162-9 [10487681.001]
  • [Cites] J Clin Endocrinol Metab. 1999 Sep;84(9):3241-7 [10487694.001]
  • [Cites] J Clin Endocrinol Metab. 2005 Apr;90(4):2104-9 [15671091.001]
  • [Cites] Ir J Med Sci. 2004 Oct-Dec;173(4):215-6 [16323617.001]
  • [Cites] J Clin Endocrinol Metab. 2006 Dec;91(12):4776-80 [16968791.001]
  • [Cites] Cancer. 1988 Jul 15;62(2):445-50 [2898285.001]
  • (PMID = 17541749.001).
  • [ISSN] 1386-341X
  • [Journal-full-title] Pituitary
  • [ISO-abbreviation] Pituitary
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Hormones; 12629-01-5 / Human Growth Hormone; RWM8CCW8GP / Octreotide
  • [Other-IDs] NLM/ PMC2045692
  •  go-up   go-down


6. Ahtiainen P, Sharp V, Rulli SB, Rivero-Müller A, Mamaeva V, Röyttä M, Huhtaniemi I: Enhanced LH action in transgenic female mice expressing hCGbeta-subunit induces pituitary prolactinomas; the role of high progesterone levels. Endocr Relat Cancer; 2010 Sep;17(3):611-21
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Enhanced LH action in transgenic female mice expressing hCGbeta-subunit induces pituitary prolactinomas; the role of high progesterone levels.
  • The etiology of pituitary adenomas remains largely unknown, with the exception of involvement of estrogens in the formation of prolactinomas.
  • We have examined the molecular pathogenesis of prolactin-producing pituitary adenomas in transgenic female mice expressing the human choriongonadotropin (hCG) beta-subunit.
  • Curiously, despite normal estrogen levels, large prolactinomas developed in these mice, and we provide here several lines of evidence that the elevated P(4) levels are involved in the growth of these estrogen-dependent tumors.
  • The antiprogestin mifepristone inhibited tumor growth, and combined postgonadectomy estradiol/P(4) treatment was more effective than estrogen alone in inducing tumor growth.
  • Evidence for direct growth-promoting effect of P(4) was obtained from cultures of primary mouse pituitary cells and rat somatomammotroph GH3 cells.
  • The mouse tumors and cultured cells revealed stimulation of the cyclin D1/cyclin-dependent kinase 4/retinoblastoma protein/transcription factor E2F1 pathway in the growth response to P(4).
  • If extrapolated to humans, and given the importance of endogenous P(4) and synthetic progestins in female reproductive functions and their pharmacotherapy, it is relevant to revisit the potential role of these hormones in the origin and growth of prolactinomas.

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. PROGESTERONE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Endocrinol Metab. 2000 Jan;85(1):168-74 [10634382.001]
  • [Cites] Endocr Relat Cancer. 2009 Mar;16(1):113-22 [18852162.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 1998 Jan;3(1):63-72 [10819505.001]
  • [Cites] J Neuroendocrinol. 2001 Mar;13(3):302-9 [11207946.001]
  • [Cites] Endocrinology. 2001 Oct;142(10):4479-85 [11564713.001]
  • [Cites] J Clin Invest. 2002 Jan;109(2):277-83 [11805140.001]
  • [Cites] Endocrinology. 2002 Oct;143(10):4084-95 [12239120.001]
  • [Cites] J Biol Chem. 2002 Sep 27;277(39):35819-25 [12121979.001]
  • [Cites] Endocrinology. 2002 Dec;143(12):4536-43 [12446580.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Feb 4;100(3):1034-9 [12552124.001]
  • [Cites] Front Horm Res. 2004;32:34-62 [15281339.001]
  • [Cites] Mol Cell Biol. 2004 Aug;24(16):7260-74 [15282324.001]
  • [Cites] Science. 1966 Oct 21;154(3747):402-3 [4288164.001]
  • [Cites] Endocrinology. 1970 Mar;86(3):503-5 [5410438.001]
  • [Cites] J Endocrinol. 1973 Feb;56(2):309-14 [4703244.001]
  • [Cites] Endocrinology. 1976 Dec;99(6):1482-9 [826392.001]
  • [Cites] J Biol Chem. 1982 Mar 10;257(5):2133-6 [7061411.001]
  • [Cites] Adv Exp Med Biol. 1981;138:151-63 [7342713.001]
  • [Cites] Arch Pathol Lab Med. 1983 Sep;107(9):488-91 [6309114.001]
  • [Cites] Cancer Res. 1985 Mar;45(3):1015-9 [2982481.001]
  • [Cites] J Endocrinol. 1989 Jun;121(3):409-17 [2547009.001]
  • [Cites] Endocrinology. 1991 Jul;129(1):270-6 [1711463.001]
  • [Cites] Nature. 1992 Sep 24;359(6393):295-300 [1406933.001]
  • [Cites] Cancer Res. 1993 Apr 1;53(7):1546-9 [8453621.001]
  • [Cites] Acta Endocrinol (Copenh). 1993 Jul;129 Suppl 1:1-5 [8396832.001]
  • [Cites] Hum Reprod. 1994 Jun;9 Suppl 1:63-8 [7962471.001]
  • [Cites] J Cell Sci Suppl. 1994;18:89-96 [7883799.001]
  • [Cites] Cancer Res. 1995 Nov 1;55(21):4892-8 [7585526.001]
  • [Cites] J Biol Chem. 1996 Aug 23;271(34):20608-16 [8702807.001]
  • [Cites] J Endocrinol. 1996 Nov;151(2):175-84 [8958777.001]
  • [Cites] Endocrinology. 1998 Apr;139(4):1602-9 [9528940.001]
  • [Cites] EMBO J. 1998 Apr 1;17(7):2008-18 [9524123.001]
  • [Cites] Nat Genet. 1998 Apr;18(4):360-4 [9537419.001]
  • [Cites] Genes Dev. 1998 Sep 15;12(18):2899-911 [9744866.001]
  • [Cites] Endocrinology. 2005 Nov;146(11):4917-25 [16123159.001]
  • [Cites] Oncogene. 2005 Nov 10;24(49):7301-9 [16007123.001]
  • [Cites] Cancer Cell. 2006 Jun;9(6):459-71 [16766265.001]
  • [Cites] J Clin Endocrinol Metab. 2006 Dec;91(12):4769-75 [16968795.001]
  • [Cites] Cell Cycle. 2008 Jan 1;7(1):71-80 [18196959.001]
  • [Cites] Horm Metab Res. 2008 Apr;40(4):245-50 [18548383.001]
  • [Cites] Eur J Endocrinol. 2008 Sep;159(3):197-202 [18567667.001]
  • [Cites] J Reprod Med. 1999 Dec;44(12 Suppl):1121-6 [10649822.001]
  • (PMID = 20453081.001).
  • [ISSN] 1479-6821
  • [Journal-full-title] Endocrine-related cancer
  • [ISO-abbreviation] Endocr. Relat. Cancer
  • [Language] ENG
  • [Grant] United Kingdom / Wellcome Trust / / 063552; United Kingdom / Wellcome Trust / / 082101
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Chorionic Gonadotropin, beta Subunit, Human; 4G7DS2Q64Y / Progesterone; 9002-62-4 / Prolactin; 9002-67-9 / Luteinizing Hormone; EC 2.7.11.22 / Cyclin-Dependent Kinase 4
  • [Other-IDs] NLM/ PMC2881531
  •  go-up   go-down


7. Park C, Yang I, Woo J, Kim S, Kim J, Kim Y, Sohn S, Kim E, Lee M, Park H, Jung J, Park S: Somatostatin (SRIF) receptor subtype 2 and 5 gene expression in growth hormone-secreting pituitary adenomas: the relationship with endogenous srif activity and response to octreotide. Endocr J; 2004 Apr;51(2):227-36
MedlinePlus Health Information. consumer health - Pituitary Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Somatostatin (SRIF) receptor subtype 2 and 5 gene expression in growth hormone-secreting pituitary adenomas: the relationship with endogenous srif activity and response to octreotide.
  • To investigate the potential pathophysiologic role of human SRIF receptor gene expression in GH-secreting adenomas in acromegalic patients, we studied the relationship between the SRIF receptor gene expression, endogenous SRIF activity and exogenous response to octreotide in 16 acromagalic patients.
  • Pituitary tumor SRIF receptor subtype 2 and 5 (sst2 and sst5) mRNA levels were measured by real-time RT-PCR.
  • These results suggest common transcriptional and/or post-transcriptonal regulatory mechanisms for these SRIF receptor subtypes within GH-secreting pituitary adenomas.
  • The functional observations suggest that the degree (or level) of sst2 and sst5 expression is critical for the ultimate GH response of somatotropinomas to endogenous SRIF tone and exogenous SRIF analogue therapy.
  • [MeSH-major] Adenoma / drug therapy. Adenoma / metabolism. Antineoplastic Agents, Hormonal / therapeutic use. Octreotide / therapeutic use. Pituitary Neoplasms / drug therapy. Pituitary Neoplasms / metabolism. Receptors, Somatostatin / metabolism
  • [MeSH-minor] Acromegaly / drug therapy. Adult. Female. Gene Expression. Human Growth Hormone / secretion. Humans. Male. Middle Aged. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15118275.001).
  • [ISSN] 0918-8959
  • [Journal-full-title] Endocrine journal
  • [ISO-abbreviation] Endocr. J.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Receptors, Somatostatin; 0 / somatostatin receptor 2; 0 / somatostatin receptor 5; 12629-01-5 / Human Growth Hormone; RWM8CCW8GP / Octreotide
  •  go-up   go-down


8. Kobayashi T, Mori Y, Uchiyama Y, Kida Y, Fujitani S: Long-term results of gamma knife surgery for growth hormone-producing pituitary adenoma: is the disease difficult to cure? J Neurosurg; 2005 Jan;102(s_supplement):119-123

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term results of gamma knife surgery for growth hormone-producing pituitary adenoma: is the disease difficult to cure?
  • OBJECT: The authors conducted a study to determine the long-term results of gamma knife surgery for residual or recurrent growth hormine (GH)-producing pituitary adenomas and to compare the results with those after treatment of other pituitary adenomas.
  • The mean tumor diameter was 19.2 mm and volume was 5.4 cm<sup>3</sup>.
  • The mean maximum dose was 35.3 Gy and the mean margin dose was 18.9 Gy.
  • The tumor resolution rate was 2%, the response rate 68.3%, and the control rate 100%.
  • Growth hormone normalization (GH < 1.0 ng/ml) was found in 4.8%, nearly normal (< 2.0 ng/ml) in 11.9%, significantly decreased (< 5.0 ng/ml) in 23.8%, decreased in 21.4%, unchanged in 21.4%, and increased in 16.7%.
  • Serum insulin-like growth factor (IGF)-1 was significantly decreased (IGF-1 < 400 ng/ml) in 40.7%, decreased in 29.6%, unchanged in 18.5%, and increased in 11.1%, which was almost parallel to the GH changes.
  • Gamma knife radiosurgery is thus indicated for small tumors after surgery or medication therapy when a relatively high-dose radiation is required.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28306435.001).
  • [ISSN] 1933-0693
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; gamma knife surgery / growth hormone—producing pituitary adenoma / insulin-like growth factor
  •  go-up   go-down


9. Rozhivanov RV, Kurbatov DG: [Sexual function rehabilitation of men with pituitary tumors]. Urologiia; 2010 Jul-Aug;(4):48, 50-3
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Sexual function rehabilitation of men with pituitary tumors].
  • A prospective trial of the methods of sexual rehabilitation of 31 men with pituitary tumors has shown that therapy with testosterone and chorionic gonadotropin effectively corrects hypogonadism and sexual disorders.
  • Both methods of treatment had no negative effect on the size of the prostatic gland and PSA level except 2 patients with somatotropinoma on testosterone.
  • In the course of chorionic gonadotropin treatment pituitary tumor increased in size in 3 patients.
  • [MeSH-major] Androgens / therapeutic use. Chorionic Gonadotropin / therapeutic use. Erectile Dysfunction / drug therapy. Hormone Replacement Therapy / methods. Pituitary Neoplasms / complications. Testosterone / therapeutic use
  • [MeSH-minor] Adult. Cohort Studies. Humans. Libido / drug effects. Male. Middle Aged. Prospective Studies. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Erectile Dysfunction.
  • MedlinePlus Health Information. consumer health - Hormone Replacement Therapy.
  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • Hazardous Substances Data Bank. TESTOSTERONE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20973135.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] Clinical Trial; English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Androgens; 0 / Chorionic Gonadotropin; 3XMK78S47O / Testosterone
  •  go-up   go-down


10. Janson ET: Treatment of neuroendocrine tumors with somatostatin analogs. Pituitary; 2006;9(3):249-56
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of neuroendocrine tumors with somatostatin analogs.
  • Neuroendocrine tumors constitute a group of hormone producing tumors originating from neuroendocrine cells in different organs.
  • Most tumors have a low proliferation index measured by Ki67 and the progression of the tumor is slow.
  • However, many patients suffer from endocrine symptoms induced by the hormones produced and released by the tumor cells.
  • For some patients these symptoms can be life- threatening as in midgut carcinoid patients suffering from carcinoid crises with extensive flushes and hypotension or in patients with severe diarrhea induced by tumors producing vasointestinal polypeptide.
  • In many other patients the hormone-induced symptoms interfere with the ability to carry out ordinary daily activities.
  • The introduction of somatostatin analogs in the treatment of these hormone related symptoms has made it possible to control most of them and has added significantly to the quality of life for this group of patients.
  • Unfortunately, the clinical inhibitory effect on tumor growth has not been very good with only 5-10% of the patients showing an objective response.
  • However, stabilization of tumor growth may be achieved in a significant number of patients.
  • [MeSH-major] Antineoplastic Agents, Hormonal / therapeutic use. Neuroendocrine Tumors / drug therapy. Somatostatin / therapeutic use
  • [MeSH-minor] Activities of Daily Living. Animals. Cell Proliferation / drug effects. Humans. Quality of Life. Receptors, Somatostatin / drug effects. Receptors, Somatostatin / metabolism. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neuroendocrinology. 2004;80(6):394-424 [15838182.001]
  • [Cites] Cancer. 1997 Apr 1;79(7):1294-8 [9083149.001]
  • [Cites] Ann Oncol. 2006 Dec;17(12):1733-42 [16801334.001]
  • [Cites] Am J Surg Pathol. 1998 Aug;22(8):934-44 [9706973.001]
  • [Cites] J Biol Chem. 2004 Aug 27;279(35):36179-83 [15231824.001]
  • [Cites] J Nucl Med. 2000 Oct;41(10 ):1704-13 [11038002.001]
  • [Cites] Ann Oncol. 2001 Oct;12(10):1383-91 [11762808.001]
  • [Cites] Curr Opin Oncol. 2002 Jan;14 (1):53-7 [11790981.001]
  • [Cites] Clin Endocrinol (Oxf). 2001 May;54(5):641-9 [11380495.001]
  • [Cites] Br J Surg. 2003 Jun;90(6):687-93 [12808615.001]
  • [Cites] J Clin Oncol. 2003 Jul 15;21(14 ):2689-96 [12860945.001]
  • [Cites] Cancer Chemother Biol Response Modif. 2003;21:535-46 [15338762.001]
  • [Cites] Ann N Y Acad Sci. 2004 Apr;1014:13-27 [15153416.001]
  • [Cites] Life Sci. 1982 Sep 13;31(11):1133-40 [6128648.001]
  • [Cites] Neuroendocrinology. 2004;80 Suppl 1:47-50 [15477717.001]
  • [Cites] Ann Oncol. 2000 Sep;11(9):1127-30 [11061606.001]
  • [Cites] Cancer. 2002 Jan 15;94(2):331-43 [11900219.001]
  • [Cites] N Engl J Med. 2000 Aug 24;343 (8):551-4 [10954763.001]
  • [Cites] Dis Colon Rectum. 1994 May;37(5):482-91 [8181412.001]
  • [Cites] Gut. 1996 Mar;38(3):430-8 [8675099.001]
  • [Cites] J Clin Oncol. 1999 Feb;17(2):600-6 [10080605.001]
  • [Cites] Med Oncol. 2003;20(1):59-67 [12665686.001]
  • [Cites] Eur J Cardiothorac Surg. 2002 May;21(5):913-7 [12062286.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Nov;88(11):5353-60 [14602773.001]
  • [Cites] J Clin Endocrinol Metab. 1993 Mar;76(3):721-7 [8095269.001]
  • [Cites] Am J Gastroenterol. 1999 May;94(5):1381-7 [10235222.001]
  • [Cites] Lancet. 1978 Jul 1;2(8079):43 [78235.001]
  • [Cites] Medicine (Baltimore). 1996 Mar;75(2):53-63 [8606627.001]
  • [Cites] Gastroenterology. 1999 Mar;116(3):532-42 [10029611.001]
  • [Cites] Scand J Gastroenterol. 2004 Jul;39(7):621-8 [15370681.001]
  • [Cites] Eur J Endocrinol. 2005 May;152(5):757-67 [15879362.001]
  • [Cites] Clin Endocrinol (Oxf). 2003 Dec;59(6):793-9 [14974924.001]
  • [Cites] Clin Endocrinol (Oxf). 1990 Aug;33(2):261-9 [1977536.001]
  • [Cites] Eur J Cancer. 1992;28A(10):1647-50 [1382492.001]
  • [Cites] Ann Thorac Surg. 2003 Dec;76(6):1838-42 [14667595.001]
  • [Cites] Acta Oncol. 1997;36(6):607-14 [9408151.001]
  • [Cites] Ann Oncol. 2004 Jun;15(6):966-73 [15151956.001]
  • [Cites] N Engl J Med. 1986 Sep 11;315(11):663-6 [2427948.001]
  • [Cites] Eur J Endocrinol. 2002 May;146(5):707-16 [11980628.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Aug;89(8):3739-44 [15292299.001]
  • [Cites] Acta Oncol. 1993;32(2):217-23 [7686764.001]
  • [Cites] Metabolism. 1996 Aug;45(8 Suppl 1):27-30 [8769375.001]
  • [Cites] Clin Endocrinol (Oxf). 2004 Sep;61(3):299-310 [15355445.001]
  • [Cites] J Clin Oncol. 1999 Apr;17 (4):1111 [10561168.001]
  • [Cites] Eur J Endocrinol. 2004 Jul;151(1):107-12 [15248829.001]
  • [Cites] Gut. 1998 Jun;42(6):792-4 [9691916.001]
  • [Cites] J Clin Endocrinol Metab. 2000 Mar;85(3):983-8 [10720027.001]
  • [Cites] Cancer. 2000 Feb 15;88(4):770-6 [10679645.001]
  • [Cites] Neuroendocrinology. 2004;80 Suppl 1:51-6 [15477718.001]
  • [Cites] Science. 1973 Jan 5;179(4068):77-9 [4682131.001]
  • [Cites] Clin Endocrinol (Oxf). 1992 Feb;36(2):183-6 [1568350.001]
  • [Cites] Ann Intern Med. 1985 Sep;103(3):363-7 [2862821.001]
  • [Cites] J Endocrinol Invest. 1997 Jun;20(6):348-67 [9294784.001]
  • (PMID = 17001461.001).
  • [ISSN] 1573-7403
  • [Journal-full-title] Pituitary
  • [ISO-abbreviation] Pituitary
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Receptors, Somatostatin; 51110-01-1 / Somatostatin
  •  go-up   go-down


11. Nasr C, Mason A, Mayberg M, Staugaitis SM, Asa SL: Acromegaly and somatotroph hyperplasia with adenomatous transformation due to pituitary metastasis of a growth hormone-releasing hormone-secreting pulmonary endocrine carcinoma. J Clin Endocrinol Metab; 2006 Dec;91(12):4776-80
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acromegaly and somatotroph hyperplasia with adenomatous transformation due to pituitary metastasis of a growth hormone-releasing hormone-secreting pulmonary endocrine carcinoma.
  • Hypothalamic gangliocytomas producing GHRH are also known to be associated with pituitary adenomas causing acromegaly.
  • OBJECTIVES: The objective of this study was to describe a case of acromegaly due to a pulmonary GHRH-secreting endocrine carcinoma with metastasis to the pituitary gland and to look at the peculiar histological features of this case.
  • SUBJECT: The patient was a 44-yr-old woman who was diagnosed with a biopsy-proven metastatic pulmonary endocrine tumor during pregnancy.
  • After delivery, she underwent radiation and chemotherapy for pulmonary and skeletal metastases.
  • Her disease was clinically stable for 7 yr until she developed bitemporal hemianopia.
  • The patient underwent uneventful transsphenoidal resection of the sellar tumor.
  • Histological examination confirmed metastatic endocrine carcinoma to the pituitary, and immunohistochemistry localized GHRH to the tumor cells.
  • The adjacent pituitary exhibited somatotroph hyperplasia with abundant reactivity for GH and alpha-subunit.
  • CONCLUSION: This is the first report of a GHRH-producing endocrine tumor metastasizing to the pituitary and causing local hyperstimulation with somatotroph hyperplasia and adenomatous transformation.
  • [MeSH-major] Acromegaly / complications. Acromegaly / etiology. Adenoma / etiology. Carcinoma / complications. Growth Hormone-Releasing Hormone / secretion. Lung Neoplasms / complications. Paraneoplastic Endocrine Syndromes / complications. Pituitary Neoplasms / secondary. Somatotrophs / pathology

  • Genetic Alliance. consumer health - Acromegaly.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16968791.001).
  • [ISSN] 0021-972X
  • [Journal-full-title] The Journal of clinical endocrinology and metabolism
  • [ISO-abbreviation] J. Clin. Endocrinol. Metab.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Hormones, Ectopic; 0 / Indium Radioisotopes; 9034-39-3 / Growth Hormone-Releasing Hormone
  •  go-up   go-down


12. Zangeneh F, Young WF Jr, Lloyd RV, Chiang M, Kurczynski E, Zangeneh F: Cushing's syndrome due to ectopic production of corticotropin-releasing hormone in an infant with ganglioneuroblastoma. Endocr Pract; 2003 Sep-Oct;9(5):394-9
MedlinePlus Health Information. consumer health - Cushing's Syndrome.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cushing's syndrome due to ectopic production of corticotropin-releasing hormone in an infant with ganglioneuroblastoma.
  • OBJECTIVE: To report the first recognized case of Cushing's syndrome due to a corticotropin-releasing hormone (CRH)-secreting ganglioneuroblastoma, which was found in an 18-month-old boy with hypertensive encephalopathy.
  • The patient had generalized obesity, decelerated linear growth, hypertrichosis, hypertension (144/103 mm Hg), hypokalemia, and proteinuria.
  • The serum adrenocorticotropic hormone (ACTH) concentration was 7 pg/mL (normal, 10 to 60), and the CRH level was 439 pg/mL (normal, 24 to 40).
  • Despite discordant dynamic endocrine testing and negative somatostatin receptor scintigraphy, computed tomography showed a right 3.6- by 3.0-cm extra-adrenal retroperitoneal mass with central calcification extending 7 cm cephalocaudally.
  • The patient underwent exploratory laparotomy, followed by chemotherapy.
  • Because most CRH-producing tumors also secrete ACTH, the ectopic production may represent a paracrine phenomenon in addition to an endocrine phenomenon.
  • The ectopic CRH may also indirectly provoke pituitary ACTH secretion.
  • This dual mechanism may explain the resistance of the tumor to feedback inhibition and a CRH-stimulation response indistinguishable from that observed in pituitary-dependent Cushing's syndrome.
  • [MeSH-major] Corticotropin-Releasing Hormone / metabolism. Cushing Syndrome / etiology. Ganglioneuroblastoma / complications. Retroperitoneal Neoplasms / complications
  • [MeSH-minor] Humans. Immunohistochemistry. Infant. Male. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Cushing's Syndrome.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14583423.001).
  • [ISSN] 1530-891X
  • [Journal-full-title] Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists
  • [ISO-abbreviation] Endocr Pract
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 9015-71-8 / Corticotropin-Releasing Hormone
  •  go-up   go-down


13. Kobayashi T, Mori Y, Uchiyama Y, Kida Y, Fujitani S: Long-term results of gamma knife surgery for growth hormone-producing pituitary adenoma: is the disease difficult to cure? J Neurosurg; 2005 Jan;102 Suppl:119-23
MedlinePlus Health Information. consumer health - Pituitary Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term results of gamma knife surgery for growth hormone-producing pituitary adenoma: is the disease difficult to cure?
  • OBJECT: The authors conducted a study to determine the long-term results of gamma knife surgery for residual or recurrent growth hormine (GH)-producing pituitary adenomas and to compare the results with those after treatment of other pituitary adenomas.
  • The mean tumor diameter was 19.2 mm and volume was 5.4 cm3.
  • The mean maximum dose was 35.3 Gy and the mean margin dose was 18.9 Gy.
  • The tumor resolution rate was 2%, the response rate 68.3%, and the control rate 100%.
  • Growth hormone normalization (GH < 1.0 ng/ml) was found in 4.8%, nearly normal (< 2.0 ng/ml) in 11.9%, significantly decreased (< 5.0 ng/ml) in 23.8%, decreased in 21.4%, unchanged in 21.4%, and increased in 16.7%.
  • Serum insulin-like growth factor (IGF)-1 was significantly decreased (IGF-1 < 400 ng/ml) in 40.7%, decreased in 29.6%, unchanged in 18.5%, and increased in 11.1%, which was almost parallel to the GH changes.
  • Gamma knife radiosurgery is thus indicated for small tumors after surgery or medication therapy when a relatively high-dose radiation is required.
  • [MeSH-major] Adenoma / secretion. Adenoma / surgery. Human Growth Hormone / secretion. Pituitary Neoplasms / secretion. Pituitary Neoplasms / surgery. Radiosurgery / instrumentation
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Follow-Up Studies. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Recurrence, Local. Outcome Assessment (Health Care). Pituitary ACTH Hypersecretion / pathology. Pituitary ACTH Hypersecretion / surgery. Prolactinoma / pathology. Prolactinoma / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15662793.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 12629-01-5 / Human Growth Hormone
  •  go-up   go-down


14. Muller AF, Van Der Lely AJ: Pharmacological therapy for acromegaly: a critical review. Drugs; 2004;64(16):1817-38
Genetic Alliance. consumer health - Acromegaly.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pharmacological therapy for acromegaly: a critical review.
  • The treatment of acromegaly has changed considerably over the last few decades.
  • In the late 1970s, the introduction of the dopamine receptor agonists made it possible to reduce growth hormone (GH) secretion by somatotropinomas for the first time.
  • Currently these compounds should be considered in patients with a mixed GH-prolactin secreting pituitary adenoma and/or those in whom pre-treatment insulin-like growth factor (IGF)-I concentrations are below 750 microg/L.
  • These compounds are capable of achieving biochemical control of GH and IGF-I in 50-60% of patients and tumour shrinkage in some 30%.
  • In particular, candidates for treatment with these compounds are those patients who have undergone an unsuccessful transsphenoidal operation or who await the therapeutic effect of external pituitary irradiation.
  • In selected patients primary medical therapy with somatostatin analogues is certainly a feasible option.
  • To date, pegvisomant is the only available member of a new class of drugs that was especially designed to block the GHR.
  • Pegvisomant is the most effective treatment for normalising IGF-I concentrations and appears to have a good safety profile.
  • However, liver function tests should be regularly monitored and tumour size should be closely followed.
  • Finally, we propose a treatment algorithm for acromegaly.
  • [MeSH-major] Acromegaly / drug therapy
  • [MeSH-minor] Adenoma / complications. Animals. Dopamine Agonists / therapeutic use. Hormone Antagonists / therapeutic use. Human Growth Hormone / antagonists & inhibitors. Human Growth Hormone / metabolism. Humans. Pituitary Neoplasms / complications. Receptors, Somatotropin / antagonists & inhibitors. Somatostatin / analogs & derivatives. Somatostatin / pharmacology. Somatostatin / therapeutic use

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Invest. 1997 Nov 1;100(9):2386-92 [9410919.001]
  • [Cites] J Clin Endocrinol Metab. 1998 Oct;83(10):3419-26 [9768641.001]
  • [Cites] Ann Intern Med. 1992 Nov 1;117(9):719-26 [1416573.001]
  • [Cites] Science. 1992 Jun 19;256(5064):1677-80 [1535167.001]
  • [Cites] Clin Endocrinol (Oxf). 1994 Jul;41(1):95-102 [8050136.001]
  • [Cites] N Engl J Med. 1990 Apr 5;322(14):966-77 [2179724.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Mar;88(3):963-8 [12629068.001]
  • [Cites] Cancer Res. 1988 Dec 15;48(24 Pt 1):6977-85 [2903792.001]
  • [Cites] Science. 1978 Oct 27;202(4366):390-402 [212832.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Jul;86(7):2976-81 [11443154.001]
  • [Cites] J Clin Endocrinol Metab. 1998 Nov;83(11):3808-16 [9814451.001]
  • [Cites] Lancet. 2001 Nov 24;358(9295):1754-9 [11734231.001]
  • [Cites] J Clin Endocrinol Metab. 2000 May;85(5):2068-71 [10843197.001]
  • [Cites] J Endocrinol Invest. 1999 Jan;22(1):40-7 [10090136.001]
  • [Cites] J Clin Endocrinol Metab. 2000 Oct;85(10):3779-85 [11061538.001]
  • [Cites] Endocr Rev. 2002 Oct;23 (5):623-46 [12372843.001]
  • [Cites] Br Med J (Clin Res Ed). 1984 Oct 27;289(6452):1101-3 [6435792.001]
  • [Cites] N Engl J Med. 1983 Sep 22;309(12 ):704-9 [6888442.001]
  • [Cites] Ann Surg. 1909 Dec;50(6):1002-17 [17862444.001]
  • [Cites] Endocr Rev. 1998 Dec;19(6):717-97 [9861545.001]
  • [Cites] Clin Endocrinol (Oxf). 2003 Feb;58(2):132-5 [12580925.001]
  • [Cites] Endocr Rev. 1988 Aug;9(3):357-73 [3145190.001]
  • [Cites] Clin Endocrinol (Oxf). 2003 Feb;58(2):128-31 [12580924.001]
  • [Cites] Clin Pharmacokinet. 2002;41(4):261-309 [11978145.001]
  • [Cites] Eur J Endocrinol. 1995 May;132(5):559-64 [7749496.001]
  • [Cites] Endocrinol Metab Clin North Am. 1989 Jun;18(2):277-310 [2663476.001]
  • [Cites] Acta Endocrinol (Copenh). 1993 May;128(5):389-93 [8100375.001]
  • [Cites] Trends Pharmacol Sci. 1995 Mar;16(3):86-8 [7792934.001]
  • [Cites] Endocr J. 1995 Apr;42(2):295-300 [7627275.001]
  • [Cites] Clin Endocrinol (Oxf). 1983 Dec;19(6):711-9 [6652932.001]
  • [Cites] J Clin Endocrinol Metab. 1998 Oct;83(10):3409-10 [9768639.001]
  • [Cites] Clin Endocrinol (Oxf). 2000 Nov;53(5):577-86 [11106918.001]
  • [Cites] Br Med J. 1975 Feb 8;1(5953):299-303 [1111790.001]
  • [Cites] J Clin Endocrinol Metab. 1981 Oct;53(4):752-8 [6793607.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 Jul;87(13):5061-5 [2367524.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Jan;86(1):140-5 [11231991.001]
  • [Cites] J Clin Endocrinol Metab. 1994 Sep;79(3):724-9 [7521350.001]
  • [Cites] N Engl J Med. 1996 Jan 25;334(4):246-54 [8532003.001]
  • [Cites] J Clin Endocrinol Metab. 1984 Jun;58(6):988-92 [6725515.001]
  • [Cites] Clin Endocrinol (Oxf). 1985 Feb;22(2):209-17 [4039234.001]
  • [Cites] J Clin Endocrinol Metab. 1997 Aug;82(8):2756 [9253368.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Sep;86(9):4072-7 [11549628.001]
  • [Cites] N Engl J Med. 1981 Jun 11;304(24):1450-4 [7015129.001]
  • [Cites] J Clin Endocrinol Metab. 2002 Apr;87(4):1797-804 [11932320.001]
  • [Cites] Eur J Endocrinol. 1994 Jul;131(1):20-6 [7913650.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Jun;86(6):2779-86 [11397887.001]
  • [Cites] N Engl J Med. 1994 Oct 6;331(14):904-9 [7915824.001]
  • [Cites] AJNR Am J Neuroradiol. 1997 Apr;18(4):765-72 [9127047.001]
  • [Cites] J Clin Endocrinol Metab. 1989 Apr;68(4):844-50 [2537844.001]
  • [Cites] Am J Cardiol. 1995 May 15;75(15):1042-7 [7747686.001]
  • [Cites] Endocrinology. 2002 Oct;143(10):4123-30 [12239124.001]
  • [Cites] Am J Med. 1980 Oct;69(4):571-5 [7424946.001]
  • [Cites] Ann N Y Acad Sci. 1994 Sep 15;733:122-37 [7978860.001]
  • [Cites] Science. 1992 Jan 17;255(5042):306-12 [1549776.001]
  • [Cites] J Mol Biol. 1991 Dec 20;222(4):865-8 [1762154.001]
  • [Cites] J Clin Endocrinol Metab. 1994 Feb;78(2):398-403 [8106629.001]
  • [Cites] Am J Pathol. 1989 Mar;134(3):605-13 [2466405.001]
  • [Cites] J Clin Endocrinol Metab. 1997 Oct;82(10):3308-14 [9329359.001]
  • [Cites] J Clin Endocrinol Metab. 2000 Aug;85(8):2958-61 [10946911.001]
  • [Cites] Br Med J. 1977 Apr 2;1(6065):875-8 [576843.001]
  • [Cites] J Clin Endocrinol Metab. 1997 Feb;82(2):518-23 [9024247.001]
  • [Cites] Ann Endocrinol (Paris). 2002 Apr;63(2 Pt 3):2S19-24 [12037499.001]
  • [Cites] Endocr Rev. 2001 Dec;22(6):724-63 [11739329.001]
  • [Cites] Clin Endocrinol (Oxf). 1988 May;28(5):551-8 [3145820.001]
  • [Cites] Ann Med. 1999 Oct;31 Suppl 2:23-7 [10574151.001]
  • [Cites] J Endocrinol Invest. 1980 Oct-Dec;3(4):405-14 [6782153.001]
  • [Cites] J Endocrinol Invest. 1999 Jun;22(6):409-18 [10435849.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Feb;86(2):478-81 [11157994.001]
  • [Cites] Clin Endocrinol (Oxf). 2000 Dec;53(6):719-24 [11155094.001]
  • [Cites] Am J Respir Crit Care Med. 2001 Sep 1;164(5):852-7 [11549545.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Jul;86(7):3304-10 [11443205.001]
  • [Cites] Pept Res. 1989 Jan-Feb;2(1):128-32 [2577697.001]
  • [Cites] Metabolism. 1996 Aug;45(8 Suppl 1):72-4 [8769388.001]
  • [Cites] J Clin Endocrinol Metab. 2002 Jul;87(7):3013-8 [12107192.001]
  • [Cites] J Clin Endocrinol Metab. 1992 Sep;75(3):812-9 [1517371.001]
  • [Cites] Diabetes. 1999 Jan;48(1):77-85 [9892225.001]
  • [Cites] J Clin Endocrinol Metab. 2000 Jul;85(7):2476-82 [10902796.001]
  • [Cites] Int J Cancer. 1997 Mar 4;70(5):530-7 [9052751.001]
  • [Cites] Acta Endocrinol Suppl (Copenh). 1978;216:207-16 [347863.001]
  • [Cites] J Biol Chem. 1997 Apr 4;272(14):9189-96 [9083050.001]
  • [Cites] Clin Endocrinol (Oxf). 1995 Jun;42(6):593-9 [7634499.001]
  • [Cites] J Clin Endocrinol Metab. 1997 Oct;82(10):3187-91 [9329336.001]
  • [Cites] Ann Intern Med. 1986 Dec;105(6):856-61 [2877605.001]
  • [Cites] J Clin Endocrinol Metab. 1994 Jul;79(1):145-51 [8027218.001]
  • [Cites] Acta Endocrinol (Copenh). 1989 Aug;121(2):286-9 [2773624.001]
  • [Cites] Laryngoscope. 1994 Apr;104(4):484-7 [8164490.001]
  • [Cites] N Engl J Med. 2000 Apr 20;342(16):1210-1 [10770989.001]
  • [Cites] Clin Endocrinol (Oxf). 1990 Jun;32(6):719-28 [2200621.001]
  • [Cites] J Clin Endocrinol Metab. 1997 Jan;82(1):18-22 [8989225.001]
  • [Cites] Mol Endocrinol. 1995 Mar;9(3):292-302 [7539887.001]
  • [Cites] J Clin Endocrinol Metab. 1993 Mar;76(3):721-7 [8095269.001]
  • [Cites] Ann Intern Med. 1984 Jan;100(1):78-91 [6229205.001]
  • [Cites] J Clin Endocrinol Metab. 1997 Aug;82(8):2755-6 [9253367.001]
  • [Cites] Annu Rev Med. 1976;27:379-88 [779605.001]
  • [Cites] J Clin Endocrinol Metab. 1985 Jun;60(6):1161-5 [2860119.001]
  • [Cites] Mol Endocrinol. 1997 Mar;11(3):265-73 [9058373.001]
  • [Cites] Recent Prog Horm Res. 1999;54:397-438; discussion 438-9 [10548885.001]
  • [Cites] Pituitary. 1999;1(2):105-14 [11081188.001]
  • [Cites] Clin Endocrinol (Oxf). 1988 Oct;29(4):411-20 [3251673.001]
  • [Cites] Eur J Endocrinol. 1999 Sep;141(3):267-71 [10474124.001]
  • [Cites] J Clin Invest. 1982 Nov;70(5):965-77 [6290540.001]
  • [Cites] Am J Cardiol. 1993 Jul 15;72 (2):205-10 [8328385.001]
  • [Cites] Endocrinology. 1994 Jan;134(1):301-6 [7903931.001]
  • [Cites] J Clin Endocrinol Metab. 2000 Feb;85(2):781-92 [10690891.001]
  • [Cites] Acta Neurochir (Wien). 1999;141(4):399-405 [10352750.001]
  • [Cites] Endocr Rev. 1991 Nov;12(4):450-82 [1684746.001]
  • [Cites] Ann Intern Med. 1990 Feb 1;112(3):173-81 [2404445.001]
  • [Cites] Clin Endocrinol (Oxf). 1989 Oct;31(4):401-10 [2627746.001]
  • [Cites] Science. 1991 Nov 8;254(5033):821-5 [1948064.001]
  • [Cites] Hosp Med. 2002 Mar;63(3):162-5 [11933820.001]
  • [Cites] J Clin Endocrinol Metab. 1995 Nov;80(11):3267-72 [7593436.001]
  • [Cites] Eur J Clin Invest. 1997 Apr;27(4):277-84 [9134375.001]
  • [Cites] J Clin Endocrinol Metab. 1998 Feb;83(2):374-8 [9467544.001]
  • [Cites] J Clin Endocrinol Metab. 1988 Nov;67(5):958-63 [2903171.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Apr;86(4):1716-23 [11297608.001]
  • [Cites] J Clin Endocrinol Metab. 2000 Feb;85(2):526-9 [10690849.001]
  • [Cites] Eur J Endocrinol. 2000 Nov;143(5):577-84 [11078980.001]
  • [Cites] J Clin Endocrinol Metab. 1974 May;38(5):910-2 [4823928.001]
  • [Cites] Endocrinology. 1994 Dec;135(6):2814-7 [7988476.001]
  • [Cites] Endocr Rev. 1995 Feb;16(1):3-34 [7758431.001]
  • [Cites] J Clin Endocrinol Metab. 2002 Sep;87(9):4054-8 [12213843.001]
  • [Cites] Ann Intern Med. 1992 Nov 1;117(9):711-8 [1416572.001]
  • [Cites] Eur J Endocrinol. 2002 May;146(5):707-16 [11980628.001]
  • [Cites] Lancet. 1999 Mar 13;353(9156):895 [10093984.001]
  • [Cites] Clin Endocrinol (Oxf). 1996 Oct;45(4):415-21 [8959079.001]
  • [Cites] J Clin Endocrinol Metab. 2000 Nov;85(11):4099-103 [11095439.001]
  • [Cites] J Biol Chem. 1994 Aug 12;269(32):20806 [8051183.001]
  • [Cites] Eur J Endocrinol. 1996 Apr;134(4):454-6 [8640297.001]
  • [Cites] Front Neuroendocrinol. 1999 Jul;20(3):157-98 [10433861.001]
  • [Cites] Metabolism. 1996 Aug;45(8 Suppl 1):27-30 [8769375.001]
  • [Cites] Horm Metab Res. 2000 Jun;32(6):224-9 [10898551.001]
  • [Cites] J Clin Endocrinol Metab. 1999 Jan;84(1):17-23 [9920056.001]
  • [Cites] Endocr Rev. 2004 Feb;25(1):102-52 [14769829.001]
  • [Cites] J Clin Endocrinol Metab. 1995 Apr;80(4):1386-92 [7714115.001]
  • [Cites] Clin Endocrinol (Oxf). 1999 Sep;51(3):275-80 [10469005.001]
  • [Cites] Endocrinology. 1991 Sep;129(3):1402-8 [1874179.001]
  • [Cites] Acta Endocrinol (Copenh). 1977 Jun;85(2):235-48 [405832.001]
  • [Cites] J Clin Endocrinol Metab. 1997 Oct;82(10):3185-6 [9329335.001]
  • [Cites] Ann Intern Med. 1994 Oct 1;121(7):478-83 [8067645.001]
  • [Cites] J Clin Endocrinol Metab. 1998 Sep;83(9):3034-40 [9745397.001]
  • [Cites] J Endocrinol. 1991 Mar;128(3):347-57 [1707433.001]
  • [Cites] J Biol Chem. 1991 Feb 5;266(4):2252-8 [1989980.001]
  • [Cites] Endocr Rev. 1995 Aug;16(4):427-42 [8521788.001]
  • [Cites] Endocrinol Metab Clin North Am. 1992 Sep;21(3):713-35 [1355728.001]
  • [Cites] J Biol Chem. 1990 Feb 25;265(6):3111-5 [2406245.001]
  • [Cites] J Clin Endocrinol Metab. 2000 Sep;85(9):3132-40 [10999798.001]
  • [Cites] Clin Endocrinol (Oxf). 2003 Feb;58(2):136-7 [12580926.001]
  • [Cites] J Clin Endocrinol Metab. 1990 Aug;71(2):391-7 [2199479.001]
  • [Cites] J Clin Endocrinol Metab. 2002 Oct;87(10):4554-63 [12364434.001]
  • [Cites] Neurobiol Aging. 1989 May-Jun;10(3):227-31 [2664540.001]
  • [Cites] Metabolism. 1992 Sep;41(9 Suppl 2):51-8 [1518434.001]
  • [Cites] Drugs. 1995 Feb;49(2):255-79 [7729332.001]
  • [Cites] Am J Cardiol. 1999 May 15;83(10 ):1506-9, A8 [10335774.001]
  • [Cites] Clin Endocrinol (Oxf). 1998 Mar;48(3):311-6 [9578821.001]
  • [Cites] Life Sci. 1995;56(5):333-42 [7530798.001]
  • [Cites] J Clin Endocrinol Metab. 1988 Nov;67(5):1040-8 [2903168.001]
  • [Cites] Endocr Rev. 2003 Feb;24(1):28-47 [12588807.001]
  • [Cites] Pituitary. 1999 Nov;2(3):205-10 [11081155.001]
  • [Cites] Pituitary. 2000 May;2(4):269-76 [11081148.001]
  • [Cites] N Engl J Med. 2000 Apr 20;342(16):1171-7 [10770982.001]
  • [Cites] Trends Endocrinol Metab. 2001 May-Jun;12(4):173-8 [11295574.001]
  • [Cites] Pituitary. 2000 Oct;3(2):61-5 [11141697.001]
  • [Cites] Endocrinol Metab Clin North Am. 1992 Sep;21(3):669-92 [1521518.001]
  • [Cites] Anesthesiology. 2000 Jul;93(1):110-4 [10861153.001]
  • [Cites] J Clin Endocrinol Metab. 1998 Aug;83(8):2730-4 [9709939.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Apr;86(4):1551-7 [11297582.001]
  • [Cites] J Clin Invest. 1997 Feb 15;99(4):789-98 [9045884.001]
  • [Cites] Metabolism. 1996 Aug;45(8 Suppl 1):67-71 [8769387.001]
  • [Cites] J Clin Endocrinol Metab. 1995 Sep;80(9):2768-75 [7673422.001]
  • [Cites] Q J Med. 1993 May;86(5):293-9 [8327647.001]
  • [Cites] J Clin Endocrinol Metab. 1978 Feb;46(2):196-202 [108287.001]
  • [Cites] J Clin Endocrinol Metab. 1996 Jun;81(6):2089-97 [8964833.001]
  • [Cites] Br J Anaesth. 2000 Feb;84(2):179-82 [10743450.001]
  • [Cites] J Neurosurg. 1994 Jul;81(1):10-4 [8207509.001]
  • [Cites] J Clin Endocrinol Metab. 1974 Feb;38(2):200-6 [4812616.001]
  • [Cites] Postgrad Med J. 1976;52suppl 1:71-4 [959128.001]
  • [Cites] J Endocrinol Invest. 1997 Jun;20(6):348-67 [9294784.001]
  • [Cites] Arch Intern Med. 1991 Aug;151(8):1573-8 [1872661.001]
  • [Cites] Acta Endocrinol (Copenh). 1977 Nov;86(3):464-72 [335755.001]
  • [Cites] Clin Endocrinol (Oxf). 1999 Mar;50(3):295-9 [10435053.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Feb;89(2):638-45 [14764775.001]
  • [Cites] J Clin Endocrinol Metab. 2002 Dec;87(12 ):5737-45 [12466380.001]
  • [Cites] Acta Endocrinol (Copenh). 1978 Apr;87(4):687-700 [417539.001]
  • (PMID = 15301564.001).
  • [ISSN] 0012-6667
  • [Journal-full-title] Drugs
  • [ISO-abbreviation] Drugs
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] New Zealand
  • [Chemical-registry-number] 0 / Dopamine Agonists; 0 / Hormone Antagonists; 0 / Receptors, Somatotropin; 12629-01-5 / Human Growth Hormone; 51110-01-1 / Somatostatin
  • [Number-of-references] 197
  •  go-up   go-down


15. Waśko R, Bolko P, Kostrzewski J, Horst-Sikorska W, Liebert W, Sowiński J: [Estimation of efficacy of the octreotide LAR administration in the patients with somatotropinoma]. Pol Arch Med Wewn; 2001 Aug;106(2):693-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Estimation of efficacy of the octreotide LAR administration in the patients with somatotropinoma].
  • [Transliterated title] Ocena skuteczności stosowania oktreotydu LAR u pacjentów z guzami przysadki typu somatotropinoma.
  • Acromegaly is caused by excessive secretion of growth hormone by a hypophyseal adenoma type of somatotropinoma.
  • Treatment of adenomas, which secrete GH, involves pharmacotherapy followed by surgery.
  • Modern pharmacotherapy leaning is based on somatostatin analogues (factor restrictive secretion GH): octreotide, octreotide LAR and lanreotide.
  • The aim of our study was estimation of efficiency of octreotide LAR in the patients with somatotropinoma prepared to neurosurgery intervention.
  • The presence of pituitary adenoma in all patients was confirmed by MRI.
  • The concentration of GH before octreotide LAR therapy in all patients increased remarkable and ranged from 15.6 to 78.6 ng/ml, mean: 31.20 +/- 16.84 (norm: 0-10 ng/ml), also, in all cases the serum IGF-I level was increased and ranged from 451 to 1107.6 ng/ml, mean: 801.75 +/- 207.82 (norm: 100-400 ng/ml).
  • Long acting somatostatin analogues--octreotide LAR is particular efficient in lowering of growth hormone and IGF-I in patients with somatotropinoma and shows efficiency in normalization of increased prolactin concentration.
  • Because of extreme effectiveness of octreotide LAR, it should be used the routine treatment at the patients suffering from active acromegaly and preparing to neurosurgical treatment.
  • [MeSH-major] Acromegaly / drug therapy. Antineoplastic Agents, Hormonal / administration & dosage. Human Growth Hormone / blood. Insulin-Like Growth Factor I / metabolism. Octreotide / administration & dosage. Peptides, Cyclic / administration & dosage. Prolactin / blood. Somatostatin / administration & dosage
  • [MeSH-minor] Adult. Aged. Female. Hormones / administration & dosage. Humans. Male. Middle Aged. Pituitary Neoplasms / diagnostic imaging. Radiography. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11926144.001).
  • [Journal-full-title] Polskie Archiwum Medycyny Wewnetrznej
  • [ISO-abbreviation] Pol. Arch. Med. Wewn.
  • [Language] pol
  • [Publication-type] Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Hormones; 0 / Peptides, Cyclic; 0G3DE8943Y / lanreotide; 12629-01-5 / Human Growth Hormone; 51110-01-1 / Somatostatin; 67763-96-6 / Insulin-Like Growth Factor I; 9002-62-4 / Prolactin; RWM8CCW8GP / Octreotide
  •  go-up   go-down


16. Casarini AP, Jallad RS, Pinto EM, Soares IC, Nonogaki S, Giannella-Neto D, Musolino NR, Alves VA, Bronstein MD: Acromegaly: correlation between expression of somatostatin receptor subtypes and response to octreotide-lar treatment. Pituitary; 2009;12(4):297-303
Genetic Alliance. consumer health - Acromegaly.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acromegaly: correlation between expression of somatostatin receptor subtypes and response to octreotide-lar treatment.
  • This study analyzes SSTR's expression in somatotrophinomas, comparing to SA response, hormonal levels, and tumor volume.
  • We analyzed 39 somatotrophinomas; 49% were treated with SA.
  • SSTR3 was more expressed in patients with tumor reduction.
  • There was a positive correlation between the percentage of tumor reduction and SSTR1, SSTR2 and SSTR3 expression.
  • [MeSH-major] Acromegaly / drug therapy. Acromegaly / metabolism. Octreotide / therapeutic use. Receptors, Somatostatin / metabolism
  • [MeSH-minor] Antineoplastic Agents, Hormonal / therapeutic use. Human Growth Hormone / metabolism. Humans. Immunohistochemistry. Insulin-Like Growth Factor I / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Somatostatin / analogs & derivatives

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Endocrinol Metab. 2005 Mar;90(3):1856-63 [15613435.001]
  • [Cites] Clin Endocrinol (Oxf). 2005 Aug;63(2):168-75 [16060910.001]
  • [Cites] Neuroendocrinology. 2004 Mar;79(3):142-8 [15103227.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Jul;86(7):2976-81 [11443154.001]
  • [Cites] J Clin Endocrinol Metab. 1999 Aug;84(8):2759-65 [10443675.001]
  • [Cites] Clin Endocrinol (Oxf). 1992 Aug;37(2):181-5 [1395069.001]
  • [Cites] BMC Biotechnol. 2003 Oct 13;3:18 [14552656.001]
  • [Cites] Eur J Endocrinol. 2002 May;146(5):701-5 [11980627.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Jan;86(1):140-5 [11231991.001]
  • [Cites] J Clin Endocrinol Metab. 1994 Sep;79(3):724-9 [7521350.001]
  • [Cites] N Engl J Med. 1996 Jan 25;334(4):246-54 [8532003.001]
  • [Cites] Clin Endocrinol (Oxf). 2000 Jan;52(1):35-42 [10651751.001]
  • [Cites] Mol Endocrinol. 2002 Nov;16(11):2502-14 [12403839.001]
  • [Cites] J Neurochem. 2004 Jun;89(5):1057-91 [15147500.001]
  • [Cites] J Biol Chem. 1978 Sep 25;253(18):6473-83 [210185.001]
  • [Cites] Cell Physiol Biochem. 2002;12 (1):31-8 [11914546.001]
  • [Cites] J Clin Endocrinol Metab. 1994 Feb;78(2):398-403 [8106629.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Jun;88(6):2797-802 [12788890.001]
  • [Cites] Front Horm Res. 2006;35:129-34 [16809928.001]
  • [Cites] J Clin Endocrinol Metab. 2005 Aug;90(8):4465-73 [15886238.001]
  • [Cites] Neuropeptides. 2001 Feb;35(1):1-23 [11346306.001]
  • [Cites] Clin Endocrinol (Oxf). 2005 Nov;63(5):514-9 [16268802.001]
  • [Cites] J Clin Endocrinol Metab. 2002 Jul;87(7):3013-8 [12107192.001]
  • [Cites] Clin Endocrinol (Oxf). 2007 Aug;67(2):310-5 [17555503.001]
  • [Cites] J Clin Endocrinol Metab. 2007 May;92(5):1592-9 [17311860.001]
  • [Cites] Eur J Endocrinol. 1995 Dec;133(6):686-90 [8548053.001]
  • [Cites] J Endocrinol Invest. 2006 Oct;29(9):826-30 [17114915.001]
  • [Cites] Eur J Endocrinol. 2005 Jul;153(1):135-41 [15994755.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Aug;86(8):3809-14 [11502816.001]
  • [Cites] Lab Invest. 2005 Aug;85(8):1040-50 [15951835.001]
  • [Cites] Eur J Endocrinol. 2007 Jan;156(1):65-74 [17218727.001]
  • [Cites] J Endocrinol Invest. 1993 Mar;16(3):181-7 [8514973.001]
  • [Cites] Endocrinology. 2002 Jul;143(7):2626-34 [12072395.001]
  • [Cites] J Clin Endocrinol Metab. 2000 Feb;85(2):781-92 [10690891.001]
  • [Cites] Endocr Rev. 1991 Nov;12(4):450-82 [1684746.001]
  • [Cites] J Clin Endocrinol Metab. 2002 Dec;87(12):5545-52 [12466351.001]
  • [Cites] Clin Endocrinol (Oxf). 2003 Jul;59(1):115-28 [12807513.001]
  • [Cites] Front Horm Res. 2004;32:235-52 [15281350.001]
  • [Cites] J Clin Pathol. 2006 Mar;59(3):274-9 [16505278.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Apr;89(4):1577-85 [15070915.001]
  • [Cites] Biochim Biophys Acta. 2003 Sep 22;1616(1):1-84 [14507421.001]
  • [Cites] Endocr Rev. 2004 Feb;25(1):102-52 [14769829.001]
  • [Cites] J Clin Endocrinol Metab. 1995 Apr;80(4):1386-92 [7714115.001]
  • [Cites] J Clin Endocrinol Metab. 1998 Sep;83(9):3034-40 [9745397.001]
  • [Cites] Endocr Rev. 1995 Aug;16(4):427-42 [8521788.001]
  • [Cites] Horm Res. 2000;53 Suppl 3:65-70 [10971108.001]
  • [Cites] Clin Endocrinol (Oxf). 1995 Mar;42(3):295-301 [7758235.001]
  • [Cites] Life Sci. 1995;56(5):333-42 [7530798.001]
  • [Cites] Endocr Rev. 2003 Feb;24(1):28-47 [12588807.001]
  • [Cites] Science. 1973 Jan 5;179(4068):77-9 [4682131.001]
  • [Cites] Endocr J. 2004 Apr;51(2):227-36 [15118275.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Jul;88(7):3090-8 [12843148.001]
  • (PMID = 19330452.001).
  • [ISSN] 1573-7403
  • [Journal-full-title] Pituitary
  • [ISO-abbreviation] Pituitary
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Receptors, Somatostatin; 0 / somatostatin receptor 2; 0 / somatostatin receptor 3; 0 / somatostatin receptor 5; 0 / somatostatin receptor subtype-4; 0 / somatostatin receptor type 1; 12629-01-5 / Human Growth Hormone; 51110-01-1 / Somatostatin; 67763-96-6 / Insulin-Like Growth Factor I; RWM8CCW8GP / Octreotide
  •  go-up   go-down


17. Saveanu A, Jaquet P: Somatostatin-dopamine ligands in the treatment of pituitary adenomas. Rev Endocr Metab Disord; 2009 Jun;10(2):83-90
MedlinePlus Health Information. consumer health - Pituitary Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Somatostatin-dopamine ligands in the treatment of pituitary adenomas.
  • Somatostatin receptors (sst1-5) and dopamine receptor 2 (D2DR) are well expressed and co-localized in several human pituitary adenomas, suggesting possible functional interactions in the control of hormonal hypersecretion and tumor cell growth.
  • The present review describes the expression and functionality of these receptors in the different classes of human pituitary adenomas.
  • The sst2 agonists, octreotide and lanreotide, control GH hypersecretion and tumor growth in about 65% of somatotropinomas.
  • Such drugs are much less effective in the control of the others pituitary adenomas also expressing ssts and D2DR receptors.
  • Such ligands bearing distinct ssts and DRD2 pharmacophores may synergistically produce an increased control of secretion and/or of proliferation in the different types of pituitary adenomas.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Pituitary Neoplasms / drug therapy. Receptors, Dopamine D2 / agonists. Receptors, Somatostatin / agonists

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Invest. 1997 Nov 1;100(9):2386-92 [9410919.001]
  • [Cites] J Biol Chem. 2003 Nov 21;278(47):46741-9 [12933819.001]
  • [Cites] Eur J Endocrinol. 2005 Apr;152(4):645-54 [15817922.001]
  • [Cites] J Biol Chem. 2001 Jun 22;276(25):22621-9 [11278324.001]
  • [Cites] Pituitary. 2001 Aug;4(3):173-8 [12138990.001]
  • [Cites] Eur J Endocrinol. 1998 Nov;139(5):516-21 [9849816.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Apr;89(4):1674-83 [15070930.001]
  • [Cites] J Med Chem. 1998 Jun 18;41(13):2175-9 [9632348.001]
  • [Cites] J Nucl Med. 2003 Aug;44(8):1315-21 [12902423.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Jan;86(1):140-5 [11231991.001]
  • [Cites] Am J Physiol Endocrinol Metab. 2005 Aug;289(2):E278-87 [15769796.001]
  • [Cites] Endocr Rev. 1992 May;13(2):220-40 [1352243.001]
  • [Cites] Nat Rev Drug Discov. 2002 Oct;1(10):808-20 [12360258.001]
  • [Cites] Mol Endocrinol. 2007 Oct;21(10):2565-78 [17609435.001]
  • [Cites] J Clin Endocrinol Metab. 1999 Sep;84(9):3268-76 [10487698.001]
  • [Cites] Cell Signal. 2007 Nov;19(11):2304-16 [17706924.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Nov;88(11):5414-21 [14602782.001]
  • [Cites] Eur J Endocrinol. 1994 Jan;130(1):80-91 [8124483.001]
  • [Cites] Biochem Biophys Res Commun. 1996 Oct 3;227(1):200-4 [8858125.001]
  • [Cites] J Clin Endocrinol Metab. 1992 Aug;75(2):540-6 [1353505.001]
  • [Cites] J Clin Endocrinol Metab. 1994 Feb;78(2):398-403 [8106629.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Jun;88(6):2797-802 [12788890.001]
  • [Cites] J Clin Endocrinol Metab. 2006 Nov;91(11):4482-8 [16940446.001]
  • [Cites] Br J Clin Pharmacol. 2004 Apr;57(4):373-87 [15025734.001]
  • [Cites] J Clin Endocrinol Metab. 2004 May;89(5):2452-62 [15126577.001]
  • [Cites] Neuroendocrinology. 2006;83(3-4):258-63 [17047391.001]
  • [Cites] J Pharmacol Exp Ther. 2000 Aug;294(2):407-12 [10900212.001]
  • [Cites] J Clin Endocrinol Metab. 2002 Jul;87(7):3013-8 [12107192.001]
  • [Cites] Int J Cancer. 1997 Mar 4;70(5):530-7 [9052751.001]
  • [Cites] Horm Res. 1997;47(4-6):227-34 [9167956.001]
  • [Cites] Eur J Endocrinol. 2005 Jul;153(1):135-41 [15994755.001]
  • [Cites] J Clin Endocrinol Metab. 2008 Apr;93(4):1412-7 [18211974.001]
  • [Cites] Am J Physiol Endocrinol Metab. 2005 Dec;289(6):E1044-50 [16046458.001]
  • [Cites] Eur J Endocrinol. 2007 Jan;156(1):65-74 [17218727.001]
  • [Cites] Endocrine. 2001 Apr;14(3):329-36 [11444429.001]
  • [Cites] J Clin Endocrinol Metab. 1972 Dec;35(6):941-3 [4634493.001]
  • [Cites] Eur J Endocrinol. 2001 Jul;145(1):35-41 [11415850.001]
  • [Cites] J Biol Chem. 2004 May 14;279(20):21374-82 [15001578.001]
  • [Cites] Eur J Endocrinol. 2008 May;158(5):595-603 [18426817.001]
  • [Cites] Eur J Nucl Med. 2001 Jul;28(7):836-46 [11504080.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Oct;89(10):5181-8 [15472224.001]
  • [Cites] J Clin Endocrinol Metab. 2000 Feb;85(2):781-92 [10690891.001]
  • [Cites] J Biol Chem. 2002 May 31;277(22):19762-72 [11896051.001]
  • [Cites] Endocr Rev. 2003 Aug;24(4):389-427 [12920149.001]
  • [Cites] J Clin Endocrinol Metab. 2002 Dec;87(12):5545-52 [12466351.001]
  • [Cites] J Biol Chem. 2001 Apr 27;276(17):14027-36 [11134004.001]
  • [Cites] EMBO Rep. 2004 Jan;5(1):30-4 [14710183.001]
  • [Cites] Clin Endocrinol (Oxf). 2000 Apr;52(4):437-45 [10762286.001]
  • [Cites] J Clin Endocrinol Metab. 1998 Feb;83(2):374-8 [9467544.001]
  • [Cites] J Biol Chem. 2000 Mar 17;275(11):7862-9 [10713101.001]
  • [Cites] Mol Endocrinol. 2003 Jan;17(1):93-106 [12511609.001]
  • [Cites] J Clin Endocrinol Metab. 1992 Nov;75(5):1318-25 [1358910.001]
  • [Cites] J Clin Endocrinol Metab. 2008 Apr;93(4):1203-10 [18198230.001]
  • [Cites] Life Sci. 2006 Jan 11;78(7):689-93 [16115652.001]
  • [Cites] Eur J Endocrinol. 2003 Apr;148(4):433-42 [12656664.001]
  • [Cites] J Pharmacol Exp Ther. 2005 Aug;314(2):485-94 [15805429.001]
  • [Cites] Science. 2000 Apr 7;288(5463):154-7 [10753124.001]
  • [Cites] Front Neuroendocrinol. 1999 Jul;20(3):157-98 [10433861.001]
  • [Cites] Trends Pharmacol Sci. 2005 Mar;26(3):131-7 [15749158.001]
  • [Cites] Clin Endocrinol (Oxf). 2005 Jul;63(1):39-44 [15963059.001]
  • [Cites] Cancer Cell Int. 2006 Mar 06;6:5 [16519802.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Sep;88(9):4239-45 [12970293.001]
  • [Cites] J Clin Endocrinol Metab. 1989 Sep;69(3):500-9 [2760167.001]
  • [Cites] J Clin Endocrinol Metab. 1992 Nov;75(5):1310-7 [1430093.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Mar 5;99(5):3294-9 [11880655.001]
  • [Cites] J Biol Chem. 2004 Sep 10;279(37):38636-43 [15247250.001]
  • [Cites] Pituitary. 1999;1(2):115-20 [11081189.001]
  • [Cites] Eur J Endocrinol. 1999 Oct;141(4):396-408 [10526255.001]
  • [Cites] Endocr Rev. 2003 Feb;24(1):28-47 [12588807.001]
  • [Cites] FEBS Lett. 2003 Aug 28;550(1-3):11-7 [12935878.001]
  • [Cites] Regul Pept. 2007 Oct 4;143(1-3):109-17 [17531331.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Feb;89(2):638-45 [14764775.001]
  • (PMID = 18651224.001).
  • [ISSN] 1573-2606
  • [Journal-full-title] Reviews in endocrine & metabolic disorders
  • [ISO-abbreviation] Rev Endocr Metab Disord
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Receptors, Dopamine D2; 0 / Receptors, Somatostatin
  • [Number-of-references] 72
  •  go-up   go-down


18. Clemmons DR, Chihara K, Freda PU, Ho KK, Klibanski A, Melmed S, Shalet SM, Strasburger CJ, Trainer PJ, Thorner MO: Optimizing control of acromegaly: integrating a growth hormone receptor antagonist into the treatment algorithm. J Clin Endocrinol Metab; 2003 Oct;88(10):4759-67
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Optimizing control of acromegaly: integrating a growth hormone receptor antagonist into the treatment algorithm.
  • Current guidelines for the treatment of acromegaly have not considered recent advances in medical therapy, in particular, the place of pegvisomant, a GH receptor antagonist.
  • Treatment goals include normalizing biochemical markers, controlling tumor mass, preserving pituitary function, and relieving signs and symptoms.
  • Surgery reduces tumor volume and is considered first-line therapy.
  • Radiation reduces tumor volume and GH and IGF-I levels, but the onset of action is slow and hypopituitarism typically develops.
  • Therefore, pharmacotherapy is often used following surgery or as first-line therapy for nonresectable tumors.
  • Dopamine agonists can be considered in patients exhibiting minimal disease or those with GH-prolactin-cosecreting tumors but will not achieve hormone normalization in most patients.
  • Pegvisomant, the newest therapeutic option, blocks GH action at peripheral receptors, normalizes IGF-I levels, reduces signs and symptoms, and corrects metabolic defects.
  • Pegvisomant does not appear to affect tumor size and has few adverse effects.
  • Pegvisomant is the most effective drug treatment for acromegaly in normalizing IGF-I and producing a clinical response; it is the preferred agent in patients resistant to or intolerant of somatostatin analogs.
  • [MeSH-major] Acromegaly / drug therapy. Growth Hormone / antagonists & inhibitors. Human Growth Hormone / therapeutic use
  • [MeSH-minor] Algorithms. Dopamine Agonists / therapeutic use. Humans

  • Genetic Alliance. consumer health - Acromegaly.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14557452.001).
  • [ISSN] 0021-972X
  • [Journal-full-title] The Journal of clinical endocrinology and metabolism
  • [ISO-abbreviation] J. Clin. Endocrinol. Metab.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Dopamine Agonists; 0 / pegvisomant; 12629-01-5 / Human Growth Hormone; 9002-72-6 / Growth Hormone
  • [Number-of-references] 92
  •  go-up   go-down


19. Pawlikowski M, Melen-Mucha G: Perspectives of new potential therapeutic applications of somatostatin analogs. Neuro Endocrinol Lett; 2003 Feb-Apr;24(1-2):21-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Perspectives of new potential therapeutic applications of somatostatin analogs.
  • At the present time only two long-acting somatostatin (SS) analogs, octreotide and lanreotide, are commonly used in the routine therapy.
  • The established indications for SS analogs treatment include acromegaly, neuroendocrine tumors of the pancreas and gastrointestinal tract, and some gastro-enterologic diseases (pancreatitis, gastrointestinal bleedings, refractory diarrheas, pancreatic and intestinal fistulas).
  • The recent investigations allow to predict the enlargement of therapeutic applications of SS analogs.
  • It concerns pituitary tumors other than somatotropinoma, tumors of other endocrine glands like thyroid and adrenal gland, as well as some non-endocrine tumors.
  • The pre- or postoperative in vivo imaging of SS receptors by means of the receptor scintigraphy, as well as the post-operative identification of SS receptor subtypes in the excised tumor tissues using immunohistochemistry, should play an important role in the prediction of the effects of SS analog treatment.
  • Beside oncology, new therapeutic applications of SS analogs could be presumed among others in ophthalmology; it concerns the treatment of progressive Graves-Basedow ophtalmopathy, diabetic retinopathy, glaucoma and corneal diseases connected with corneal vascularization.
  • [MeSH-major] Hormone Antagonists / therapeutic use. Somatostatin / analogs & derivatives. Somatostatin / therapeutic use
  • [MeSH-minor] Acromegaly / drug therapy. Animals. Antineoplastic Agents, Hormonal / therapeutic use. Endocrine Gland Neoplasms / drug therapy. Humans. Receptors, Somatostatin / drug effects

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12743527.001).
  • [ISSN] 0172-780X
  • [Journal-full-title] Neuro endocrinology letters
  • [ISO-abbreviation] Neuro Endocrinol. Lett.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Sweden
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Hormone Antagonists; 0 / Receptors, Somatostatin; 51110-01-1 / Somatostatin
  • [Number-of-references] 72
  •  go-up   go-down


20. Kovacs K, Horvath E: Effects of medical therapy on pituitary tumors. Ultrastruct Pathol; 2005 May-Aug;29(3-4):163-7
MedlinePlus Health Information. consumer health - Pituitary Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effects of medical therapy on pituitary tumors.
  • Previously surgery and irradiation were the only available procedures to treat patients with pituitary tumors.
  • During the last few decades, novel drugs such as dopamine agonists and long-acting somatostatin analogs were developed and, an alternative medical therapy emerged.
  • This paper summarizes the effect of medical therapy on the morphologic features of pituitary tumors and illustrates the ultrastructural alterations on electron micrographs.
  • Currently drugs can be used in the management of pituitary tumors secreting GH, PRL, and/or TSH in excess.
  • No medical therapy is available so far for ACTH-, FSH-, LH-, or alpha-subunit-secreting tumors as well as non-hormone-secreting pituitary tumors.
  • Dopamine agonists are effective in the management of PRL-secreting tumors; they cause marked reversible tumor shrinkage in the substantial majority of patients.
  • Long-acting somatostatin analogs are useful in the management of GH- and TSH-secreting pituitary tumors; they lead to mild to moderate tumor shrinkage in approximately 50% of cases.
  • In patients treated with these drugs reduction of elevated blood hormone levels and amelioration of clinical symptoms ensue.
  • Blood hormone levels increase and the clinical symptoms reappear after discontinuation of treatment.
  • Recently GH receptor blockers (pegvisomant) were introduced in the treatment of GH-producing pituitary adenomas.
  • To the authors' knowledge the effect of these drugs on the morphology of pituitary tumors has not been revealed so far.
  • [MeSH-major] Dopamine Agonists / therapeutic use. Human Growth Hormone / analogs & derivatives. Octreotide / therapeutic use. Pituitary Neoplasms / drug therapy
  • [MeSH-minor] Humans. Microscopy, Electron, Transmission. Prolactin / secretion. Thyrotropin / secretion. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16036872.001).
  • [ISSN] 0191-3123
  • [Journal-full-title] Ultrastructural pathology
  • [ISO-abbreviation] Ultrastruct Pathol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Dopamine Agonists; 0 / pegvisomant; 12629-01-5 / Human Growth Hormone; 9002-62-4 / Prolactin; 9002-71-5 / Thyrotropin; RWM8CCW8GP / Octreotide
  •  go-up   go-down


21. Donangelo I, Rodacki M, Peixoto MC, Vaisman M, Caldas NR, Gadelha MR: Dependency and analgesia related to treatment with subcutaneous octreotide in patients with growth hormone-secreting tumors. Endocr Pract; 2004 Mar-Apr;10(2):107-11
MedlinePlus Health Information. consumer health - Pituitary Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dependency and analgesia related to treatment with subcutaneous octreotide in patients with growth hormone-secreting tumors.
  • OBJECTIVE: To describe three patients diagnosed with somatotropinomas in whom the analgesic effect of octreotide was observed, along with dependency to the drug.
  • METHODS: These patients had pituitary macroadenomas treated with transphenoidal surgery and pituitary radiotherapy, and received high daily doses (>900 microg/day) of subcutaneous octreotide because of persistent high levels of growth hormone and insulin-like growth factor I (IGF-I).
  • RESULTS: Headache occurred prior to drug administration in all three cases, with relief soon after.
  • We also observed tolerance to octreotide's analgesic and anti-secretory actions (one patient), craving for the drug (two patients), withdrawal syndrome (one patient), and drug abuse (one patient).
  • CONCLUSION: Dependency syndrome may occur when high doses of octreotide are used, sometimes leading to drug abuse.
  • Tolerance to the growth hormone anti-secretory effect of the drug may encourage physicians to increase doses to levels at which drug dependency has been observed.
  • [MeSH-major] Adenoma / drug therapy. Adenoma / secretion. Antineoplastic Agents, Hormonal / adverse effects. Human Growth Hormone / secretion. Octreotide / adverse effects. Pituitary Neoplasms / drug therapy. Pituitary Neoplasms / secretion. Substance-Related Disorders
  • [MeSH-minor] Adolescent. Adult. Combined Modality Therapy. Drug Tolerance. Female. Humans. Middle Aged

  • MedlinePlus Health Information. consumer health - Drug Abuse.
  • MedlinePlus Health Information. consumer health - Drugs and Young People.
  • MedlinePlus Health Information. consumer health - Opioid Abuse and Addiction.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15256326.001).
  • [ISSN] 1530-891X
  • [Journal-full-title] Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists
  • [ISO-abbreviation] Endocr Pract
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 12629-01-5 / Human Growth Hormone; RWM8CCW8GP / Octreotide
  •  go-up   go-down


22. Mezosi E, Nemes O: [Treatment of pituitary adenomas]. Orv Hetil; 2009 Sep 27;150(39):1803-10
Hazardous Substances Data Bank. Corticotropin .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Treatment of pituitary adenomas].
  • According to epidemiological studies, the prevalence of pituitary adenomas is 16.5% and the majority of them are "incidentalomas".
  • The symptoms of pituitary disorders are often non-specific; disturbances of pituitary function, compression symptoms, hypophysis apoplexy or accidental findings may help the diagnosis.
  • The hormonal evaluation of pituitary adenomas is different from the algorithm used in the disorders of peripheral endocrine organs.
  • The first-line therapy of prolactinomas are the dopamine agonists, and the aims of the treatment are to normalize the prolactin level, restore fertility in child-bearing age, decrease tumor mass, save or improve the residual pituitary function and inhibit the relapse of the disease.
  • In case of tumors with good therapeutic response, medical therapy can be withdrawn after 3-5 years; hyperprolactinemia will not recur in 2/3 of these patients.
  • Neurosurgery is the primary therapy of GH-, ACTH-, TSH-producing and inactive adenomas.
  • Acromegalic patients with unresectable tumors have a great benefit from somatostatin analog treatment.
  • The growth hormone receptor antagonist pegvisomant is the newest modality for the treatment of acromegaly.
  • The medical therapy of Cushing's disease is still based on the inhibition of steroid production.
  • The rare TSH-producing tumor can respond to both dopamine agonist and somatostatin analog therapy.
  • The application of conventional radiotherapy has decreased; radiotherapy is mainly used in the treatment of invasive, incurable or malignant tumors.
  • Further studies are needed to elucidate the exact role of radiosurgery and fractionated stereotaxic irradiation in the treatment of pituitary tumors.
  • [MeSH-major] Adenoma / therapy. Pituitary Hormones / blood. Pituitary Neoplasms / therapy
  • [MeSH-minor] ACTH-Secreting Pituitary Adenoma / therapy. Acromegaly / drug therapy. Acromegaly / etiology. Adrenocorticotropic Hormone / blood. Aminoquinolines / therapeutic use. Bromocriptine / therapeutic use. Cushing Syndrome / drug therapy. Cushing Syndrome / etiology. Dopamine Agonists / therapeutic use. Female. Growth Hormone-Secreting Pituitary Adenoma / therapy. Human Growth Hormone / analogs & derivatives. Human Growth Hormone / blood. Human Growth Hormone / therapeutic use. Humans. Hypophysectomy. Incidental Findings. Male. Pregnancy. Pregnancy Complications, Neoplastic / therapy. Prolactinoma / therapy. Radiosurgery. Receptors, Somatotropin / antagonists & inhibitors. Somatostatin / analogs & derivatives. Somatostatin / therapeutic use. Thyrotropin / blood

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19758960.001).
  • [ISSN] 0030-6002
  • [Journal-full-title] Orvosi hetilap
  • [ISO-abbreviation] Orv Hetil
  • [Language] hun
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Hungary
  • [Chemical-registry-number] 0 / Aminoquinolines; 0 / Dopamine Agonists; 0 / Pituitary Hormones; 0 / Receptors, Somatotropin; 0 / pegvisomant; 12629-01-5 / Human Growth Hormone; 3A64E3G5ZO / Bromocriptine; 51110-01-1 / Somatostatin; 80Q9QWN15M / quinagolide; 9002-60-2 / Adrenocorticotropic Hormone; 9002-71-5 / Thyrotropin; 98H1T17066 / pasireotide
  • [Number-of-references] 28
  •  go-up   go-down


23. Nieman LK, Ilias I: Evaluation and treatment of Cushing's syndrome. Am J Med; 2005 Dec;118(12):1340-6
Hazardous Substances Data Bank. Corticotropin .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation and treatment of Cushing's syndrome.
  • Cushing's syndrome results from sustained pathologic hypercortisolism caused by excessive corticotropin (ACTH) secretion by tumors in the pituitary gland (Cushing's disease, 70%) or elsewhere (15%), or by ACTH-independent cortisol secretion from adrenal tumors (15%).
  • Those features most specific for Cushing's syndrome include abnormal fat distribution, particularly in the supraclavicular and temporal fossae, proximal muscle weakness, wide purple striae, and decreased linear growth with continued weight gain in a child.
  • In ACTH-dependent patients, bilateral inferior petrosal sinus sampling with measurement of ACTH before and after administration of ACTH-releasing hormone most accurately distinguishes pituitary from ectopic ACTH secretion.
  • Surgical resection of tumor is the optimal treatment for all forms of Cushing's syndrome; bilateral adrenalectomy, medical treatment, or radiotherapy are sought in inoperable or recurrent cases.
  • The medical treatment of choice is ketoconazole.
  • The prognosis is better for Cushing's disease and benign adrenal causes of Cushing's syndrome than adrenocortical cancer and malignant ACTH-producing tumors.
  • [MeSH-major] Adrenocorticotropic Hormone / blood. Cushing Syndrome / diagnosis. Cushing Syndrome / drug therapy
  • [MeSH-minor] Adrenalectomy. Adult. Antifungal Agents / therapeutic use. Child. Diagnosis, Differential. Humans. Ketoconazole / therapeutic use. Prognosis. Recurrence. Survival Analysis

  • Genetic Alliance. consumer health - Cushing's Syndrome.
  • MedlinePlus Health Information. consumer health - Cushing's Syndrome.
  • Hazardous Substances Data Bank. KETOCONAZOLE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16378774.001).
  • [ISSN] 1555-7162
  • [Journal-full-title] The American journal of medicine
  • [ISO-abbreviation] Am. J. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antifungal Agents; 9002-60-2 / Adrenocorticotropic Hormone; R9400W927I / Ketoconazole
  • [Number-of-references] 100
  •  go-up   go-down


24. Wasko R, Sawicka J, Stachowiak C, Kozak W, Junik R, Sowinski J: [Effect of lanreotide on prolactin level in patients with pituitary mixed tumors]. Ann Endocrinol (Paris); 2002 Dec;63(6 Pt 1):532-5
MedlinePlus Health Information. consumer health - Pituitary Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Effect of lanreotide on prolactin level in patients with pituitary mixed tumors].
  • [Transliterated title] Influence du lanréotide sur la concentration sérique de prolactine chez les patients atteints de tumeurs somato-lactotropes.
  • Acromegaly is a disease caused by a pituitary tumor (somatotropinoma) or by ectopic secretion of GH or IGF-1.
  • Last time a lanreotide and an octreotide (the somatostatine analogues) are useful in the therapy of acromegaly.
  • We noticed that the lanreotide caused not only serum level reduction of a growth hormone but also prolactine in patients with mixed pituitary tumors.
  • [MeSH-major] Acromegaly / etiology. Antineoplastic Agents / therapeutic use. Peptides, Cyclic / therapeutic use. Pituitary Neoplasms / blood. Pituitary Neoplasms / drug therapy. Prolactin / blood. Somatostatin / analogs & derivatives. Somatostatin / therapeutic use
  • [MeSH-minor] Adult. Female. Follow-Up Studies. Growth Hormone / secretion. Human Growth Hormone / blood. Humans. Male. Middle Aged. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12527855.001).
  • [ISSN] 0003-4266
  • [Journal-full-title] Annales d'endocrinologie
  • [ISO-abbreviation] Ann. Endocrinol. (Paris)
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Peptides, Cyclic; 118992-92-0 / lanreotide; 12629-01-5 / Human Growth Hormone; 51110-01-1 / Somatostatin; 9002-62-4 / Prolactin; 9002-72-6 / Growth Hormone
  •  go-up   go-down


25. Waśko R, Bolko P, Owecki M, Jaskuła M, Sowiński J: The efficacy of octreotide LAR (long acting release) treatment in patients with somatotropinoma, and mixed pituitary tumours. Pharm World Sci; 2004 Dec;26(6):324-7
MedlinePlus Health Information. consumer health - Pituitary Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The efficacy of octreotide LAR (long acting release) treatment in patients with somatotropinoma, and mixed pituitary tumours.
  • OBJECTIVE: The efficacy of somatostatin analogues in the treatment of acromegaly is not always equal and therefore we wanted to evaluate the efficacy of therapy with octreotide long acting release (LAR) in patients with monohormonal tumours (somatotropinomas) in comparison to individuals with mixed pituitary tumours secreting alpha-subunit.
  • METHOD: The 35 acromegalic patients (18 males and 17 females), aged 41.8 +/- 8.8 years, were divided into 2 groups according to the secreted hormones: 1 with mixed pituitary tumours with elevated growth hormone and alpha-subunit concentrations, the other with isolated growth hormone hypersecretion and normal alpha-subunit levels.
  • RESULTS: The decrease of GH and IGF-I levels after octreotide LAR treatment were observed in both groups.
  • CONCLUSIONS: After octreotide LAR treatment, the decrease of GH level and of mean IGF-I values was greater in patients with mixed pituitary tumours and high alpha-subunit concentrations than in patients with isolated GH hypersecretion and normal alpha-subunit levels.
  • [MeSH-major] Adenoma / drug therapy. Antineoplastic Agents, Hormonal / therapeutic use. Octreotide / therapeutic use. Pituitary Neoplasms / drug therapy
  • [MeSH-minor] Acromegaly / drug therapy. Acromegaly / etiology. Adult. Delayed-Action Preparations. Female. Human Growth Hormone / blood. Humans. Insulin-Like Growth Factor I / metabolism. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15683101.001).
  • [ISSN] 0928-1231
  • [Journal-full-title] Pharmacy world & science : PWS
  • [ISO-abbreviation] Pharm World Sci
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Delayed-Action Preparations; 12629-01-5 / Human Growth Hormone; 67763-96-6 / Insulin-Like Growth Factor I; RWM8CCW8GP / Octreotide
  •  go-up   go-down


26. Imai A, Tamaya T: GnRH receptor and apoptotic signaling. Vitam Horm; 2000;59:1-33
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In addition to its hypophysiotropic action, gonadotropin-releasing hormone (GnRH) can modify activity in extrapituitary organs and peripheral tumors.
  • GnRH analogs are the preferred treatment for advanced and even metastatic or recurring carcinomas in vivo and in vitro.
  • Hormone-responsive tumors undergo apoptosis with the appropriate stimulus; GnRH-induced tumor growth arrest may result from stimulated apoptotic cell death.
  • The sensitivity of tumors and normal tissue to GnRH is strongly associated with the possession of receptors for GnRH as well as other hormonal control.
  • GnRH receptors in tumors differ from those in pituitary gonadotrophs in some aspects, in particular with regard to the transmembrane signaling cascade.
  • The intramembranous phenomena that occur independently of the contribution of other organelles upon tumoral GnRH receptor engagement include (i) activation of phosphotyrosine phosphatase and loss of phosphotyrosine from the endogenous membrane protein and (ii) phosphoinositide and perhaps sphingomyelin cleavage producing lipid-originated second messengers.
  • The Fas-Fas ligand complex might, at least in part, account for the antiproliferative action of the hormone.
  • An understanding of the relationship between the extracellular (hormonal) stimuli that leads to cell death and the intracellular events regulating growth arrest on GnRH action may fundamentally help clarify the therapeutic approach to all hormone-dependent carcinomas that respond to stimuli that lead to apoptosis.
  • [MeSH-major] Apoptosis / physiology. Fertility Agents, Female / therapeutic use. Gonadotropin-Releasing Hormone / physiology. Neoplasms, Hormone-Dependent / drug therapy. Receptors, LHRH / physiology

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10714235.001).
  • [ISSN] 0083-6729
  • [Journal-full-title] Vitamins and hormones
  • [ISO-abbreviation] Vitam. Horm.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Antigens, CD95; 0 / Fertility Agents, Female; 0 / Phosphatidylinositols; 0 / Receptors, LHRH; 33515-09-2 / Gonadotropin-Releasing Hormone; EC 3.1.3.48 / Protein Tyrosine Phosphatases
  • [Number-of-references] 184
  •  go-up   go-down


27. Ning S, Knox SJ, Harsh GR, Culler MD, Katznelson L: Lanreotide promotes apoptosis and is not radioprotective in GH3 cells. Endocr Relat Cancer; 2009 Sep;16(3):1045-55
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Somatostatin analogs are a mainstay of medical therapy in patients with GH producing human pituitary tumors, and it has been suggested that somatostatin analogs may be radioprotective.
  • We utilized GH secreting rat GH3 cells to investigate whether a somatostatin analog may limit the effects of radiation on proliferation and apoptosis in vitro and on tumor growth in vivo.
  • Treatment with lanreotide alone at doses of either 100 or 1000 nM for 48 h reduced clonogenic survival by 5-10%.
  • In a mouse GH3 tumor xenograft model, lanreotide 10 mg/kg moderately inhibited the growth of GH3 tumors, with a 4x tumor growth delay (TGD) time that ranged from 4.5 to 8.3 days.
  • Fractionated local tumor radiation alone significantly inhibited tumor growth and produced a TGD of 35.1+/-5.7 days for 250 cGy fractions.
  • The combination of lanreotide, either antecedent to or concurrent, with radiation of 250, 200 or 150 cGy/fraction for 5 days inhibited tumor growth and produced the TGD times that were similar to radiation alone (P>0.05).
  • [MeSH-major] Adenoma / pathology. Apoptosis / drug effects. Growth Hormone-Secreting Pituitary Adenoma / pathology. Peptides, Cyclic / pharmacology. Radiation Tolerance / drug effects. Somatostatin / analogs & derivatives. Somatotrophs / pathology
  • [MeSH-minor] Animals. Antineoplastic Agents / pharmacology. Cell Line, Tumor. Cell Survival / drug effects. Cell Survival / radiation effects. Dose-Response Relationship, Drug. Gamma Rays. Male. Mice. Mice, Nude. Radiation Dosage. Radiation-Protective Agents / pharmacology. Rats. Xenograft Model Antitumor Assays

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19528243.001).
  • [ISSN] 1479-6821
  • [Journal-full-title] Endocrine-related cancer
  • [ISO-abbreviation] Endocr. Relat. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Peptides, Cyclic; 0 / Radiation-Protective Agents; 118992-92-0 / lanreotide; 51110-01-1 / Somatostatin
  •  go-up   go-down


28. Wasko R, Jankowska A, Kotwicka M, Liebert W, Sowinski J, Warchol JB: Effects of treatment with somatostatin analogues on the occurrence of apoptosis in somatotropinomas. Neuro Endocrinol Lett; 2003 Oct;24(5):334-8
MedlinePlus Health Information. consumer health - Pituitary Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effects of treatment with somatostatin analogues on the occurrence of apoptosis in somatotropinomas.
  • Present study aimed to examine whether treatment of somatotropinoma types tumours with somatostatine analogue (lanreotide) results in apoptosis.
  • MATERIAL AND METHODS: The studies were performed on 35 patients with somatotropinoma type tumours on whom adenomectomy was performed by transsphenoidal approach.
  • The results of the studies demonstrated the occurrence of lanreotide induced apoptosis in somatotropinoma type tumours.
  • The grade of apoptotic cells in macroadenomas type adenomas, treated with lanreotide, ranged from 4.0% to 17.1% (mean 8.7+/-2.6%).
  • Patients in whom hypophysectomy was not preceded by lanreotide treatment demonstrated low level of apoptotic cells (no more than 3.5%).
  • CONCLUSIONS: The studies showed that treatment with somatostatine analogue-lanreotide induced apoptosis of tumour cell suggesting that the induction of apoptotic cell death may be involved in the anticancer activity of somatostatine analogue.
  • [MeSH-major] Adenoma / drug therapy. Antineoplastic Agents / administration & dosage. Apoptosis / drug effects. Peptides, Cyclic / administration & dosage. Pituitary Neoplasms / drug therapy. Somatostatin / administration & dosage

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14647007.001).
  • [ISSN] 0172-780X
  • [Journal-full-title] Neuro endocrinology letters
  • [ISO-abbreviation] Neuro Endocrinol. Lett.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Sweden
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Peptides, Cyclic; 118992-92-0 / lanreotide; 51110-01-1 / Somatostatin
  •  go-up   go-down


29. Vance ML: Medical treatment of functional pituitary tumors. Neurosurg Clin N Am; 2003 Jan;14(1):81-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Medical treatment of functional pituitary tumors.
  • Medical therapy with a dopamine agonist is the most effective for treatment of a prolactin-producing adenoma and is considered as primary treatment.
  • Surgery and pituitary radiation are reserved for patients who either do not tolerate or do not respond to a dopamine agonist drug.
  • A somatostatin analogue is effective medical therapy for patients with acromegaly, and this is usually administered if there is persistent GH hypersecretion after surgical resection.
  • Medical treatment for patients with Cushing's disease is directed at the adrenal glands to reduce cortisol hypersecretion.
  • Unfortunately, there is no effective medical therapy to reduce pituitary corticotropin production.
  • Medical therapy for a gonadotrope adenoma with a dopamine agonist or somatostatin analogue has limited utility but is employed in patients who are unable to undergo surgery and may delay or prevent additional tumor growth.
  • Many patients with a pituitary adenoma can be successfully treated with one treatment, either a dopamine agonist for a prolactinoma or surgery for other types of tumors.
  • A substantial number of patients require multimodality therapy, however, including medical therapy, surgery, and pituitary radiation.
  • Because the biologic behavior of pituitary adenomas varies considerably, a patient with a pituitary adenoma requires lifelong regular monitoring for hormone hypersecretion, tumor recurrence, and development of new pituitary hormone deficiency.
  • [MeSH-major] Adenoma / drug therapy. Pituitary Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12690980.001).
  • [ISSN] 1042-3680
  • [Journal-full-title] Neurosurgery clinics of North America
  • [ISO-abbreviation] Neurosurg. Clin. N. Am.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 53
  •  go-up   go-down


30. Akaza I, Tsuchiya K, Akaza M, Sugiyama T, Izumiyama H, Doi M, Yoshimoto T, Hirata Y: Improvement of congestive heart failure after octreotide and transsphenoidal surgery in a patient with acromegaly. Intern Med; 2009;48(9):697-700
MedlinePlus Health Information. consumer health - Heart Failure.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • He was suspected to have acromegaly, and magnetic resonance imaging revealed a pituitary macroadenoma.
  • Endocrine examination revealed elevated plasma levels of growth hormone (GH) and insulin-like growth factor (IGF)-1, and an oral glucose tolerance test failed to suppress plasma GH levels, consistent with the diagnosis of GH-producing pituitary tumor.
  • Treatment with octreotide, followed by transsphenoidal surgery resulted in normalization of plasma GH/IGF-1 levels, accompanied by the improvement of cardiac function.
  • [MeSH-major] Acromegaly / drug therapy. Acromegaly / surgery. Heart Failure / drug therapy. Heart Failure / surgery. Octreotide / therapeutic use

  • Genetic Alliance. consumer health - Acromegaly.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19420816.001).
  • [ISSN] 1349-7235
  • [Journal-full-title] Internal medicine (Tokyo, Japan)
  • [ISO-abbreviation] Intern. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] RWM8CCW8GP / Octreotide
  •  go-up   go-down


31. Neto LV, Machado Ede O, Luque RM, Taboada GF, Marcondes JB, Chimelli LM, Quintella LP, Niemeyer P Jr, de Carvalho DP, Kineman RD, Gadelha MR: Expression analysis of dopamine receptor subtypes in normal human pituitaries, nonfunctioning pituitary adenomas and somatotropinomas, and the association between dopamine and somatostatin receptors with clinical response to octreotide-LAR in acromegaly. J Clin Endocrinol Metab; 2009 Jun;94(6):1931-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression analysis of dopamine receptor subtypes in normal human pituitaries, nonfunctioning pituitary adenomas and somatotropinomas, and the association between dopamine and somatostatin receptors with clinical response to octreotide-LAR in acromegaly.
  • CONTEXT: Dopamine receptor (DR) and somatostatin receptor subtype expression in pituitary adenomas may predict the response to postsurgical therapies.
  • OBJECTIVES: Our objectives were to assess and compare the mRNA levels of DR1-5 and somatostatin receptors 1-5 in normal pituitaries (NPs), nonfunctioning pituitary adenomas (NFPAs), and somatotropinomas.
  • DESIGN AND PATIENTS: Eight NPs, 30 NFPAs, and 39 somatotropinomas were analyzed for receptor mRNA levels by real-time RT-PCR.
  • The relationship between expression levels of DR subtypes in NPs and somatotropinomas was DR2T>>>DR4>>DR5>DR1, whereas in NFPAs, DR2T>>>DR4>>DR1>DR5.
  • CONCLUSIONS: DR2 is the predominant DR subtype in NPs, NFPAs, and somatotropinomas.
  • The fact that DR1, DR4, and DR5 are also expressed in many adenomas tested suggests that these receptors might also play a role in the therapeutic impact of postsurgical medical therapies in patients with NFPA and acromegaly.

  • Genetic Alliance. consumer health - Acromegaly.
  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Science. 2000 Apr 7;288(5463):154-7 [10753124.001]
  • [Cites] Rev Endocr Metab Disord. 2009 Jun;10(2):83-90 [18651224.001]
  • [Cites] Clin Endocrinol (Oxf). 2001 Apr;54(4):469-77 [11318782.001]
  • [Cites] Endocrine. 2001 Apr;14(3):329-36 [11444429.001]
  • [Cites] J Neurophysiol. 2002 Apr;87(4):2167-75 [11929934.001]
  • [Cites] Genome Biol. 2002 Jun 18;3(7):RESEARCH0034 [12184808.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Apr;89(4):1674-83 [15070930.001]
  • [Cites] J Biol Chem. 1978 Apr 10;253(7):2244-53 [416027.001]
  • [Cites] J Histochem Cytochem. 1979 Aug;27(8):1205-7 [383827.001]
  • [Cites] Endocrinology. 1983 May;112(5):1567-77 [6832061.001]
  • [Cites] Proc Soc Exp Biol Med. 1984 Feb;175(2):191-5 [6694976.001]
  • [Cites] Brain Res. 1988 Mar 8;443(1-2):77-84 [2896059.001]
  • [Cites] EMBO J. 1989 Dec 20;8(13):4025-34 [2531656.001]
  • [Cites] Nature. 1989 Dec 21-28;342(6252):923-6 [2531847.001]
  • [Cites] FEBS Lett. 1990 Apr 9;263(1):18-22 [2139615.001]
  • [Cites] Biochemistry. 1990 Feb 13;29(6):1367-71 [2139794.001]
  • [Cites] J Neurochem. 1991 Mar;56(3):1024-9 [1825222.001]
  • [Cites] J Neurochem. 1991 Sep;57(3):795-801 [1861151.001]
  • [Cites] Neurosci Lett. 1991 Sep 2;130(1):12-6 [1836253.001]
  • [Cites] Nature. 1992 Jul 9;358(6382):149-52 [1319557.001]
  • [Cites] Mol Endocrinol. 1992 Jun;6(6):920-6 [1323056.001]
  • [Cites] Mol Endocrinol. 1992 Nov;6(11):1815-24 [1282671.001]
  • [Cites] Annu Rev Pharmacol Toxicol. 1993;33:281-307 [8494342.001]
  • [Cites] Neuroendocrinology. 1994 Sep;60(3):314-22 [7969790.001]
  • [Cites] J Neurochem. 1995 Sep;65(3):1157-65 [7643093.001]
  • [Cites] Anal Biochem. 1995 Sep 20;230(2):353-5 [7503432.001]
  • [Cites] Endocrinology. 1997 May;138(5):1871-8 [9112381.001]
  • [Cites] Physiol Rev. 1998 Jan;78(1):189-225 [9457173.001]
  • [Cites] J Clin Endocrinol Metab. 1998 Feb;83(2):374-8 [9467544.001]
  • [Cites] J Clin Endocrinol Metab. 1998 Apr;83(4):1368-75 [9543168.001]
  • [Cites] Brain Res Mol Brain Res. 1998 Apr;55(2):285-92 [9582438.001]
  • [Cites] Endocrinology. 1998 Oct;139(10):4213-21 [9751502.001]
  • [Cites] Biochem Biophys Res Commun. 1999 Mar 5;256(1):33-40 [10066418.001]
  • [Cites] J Mol Endocrinol. 2005 Oct;35(2):333-41 [16216913.001]
  • [Cites] Trends Pharmacol Sci. 2005 Nov;26(11):595-602 [16183138.001]
  • [Cites] Neuroendocrinology. 2006;83(3-4):258-63 [17047391.001]
  • [Cites] Eur J Endocrinol. 2007 Jan;156(1):65-74 [17218727.001]
  • [Cites] Eur J Endocrinol. 2007 Apr;156 Suppl 1:S13-21 [17413183.001]
  • [Cites] Eur J Endocrinol. 2007 Apr;156 Suppl 1:S23-8 [17413184.001]
  • [Cites] Eur J Endocrinol. 2007 Apr;156 Suppl 1:S37-43 [17413187.001]
  • [Cites] Eur J Endocrinol. 2007 Apr;156 Suppl 1:S57-63 [17413190.001]
  • [Cites] Cell Signal. 2007 Nov;19(11):2304-16 [17706924.001]
  • [Cites] J Neuroendocrinol. 2007 Oct;19(10):773-8 [17850459.001]
  • [Cites] Eur J Endocrinol. 2008 Mar;158(3):295-303 [18299461.001]
  • [Cites] J Clin Endocrinol Metab. 2008 Apr;93(4):1412-7 [18211974.001]
  • [Cites] Mol Pharmacol. 2000 Aug;58(2):455-62 [10908315.001]
  • (PMID = 19293270.001).
  • [ISSN] 1945-7197
  • [Journal-full-title] The Journal of clinical endocrinology and metabolism
  • [ISO-abbreviation] J. Clin. Endocrinol. Metab.
  • [Language] ENG
  • [Grant] United States / PHS HHS / / 30677
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Delayed-Action Preparations; 0 / Protein Isoforms; 0 / RNA, Messenger; 0 / Receptors, Dopamine; 0 / Receptors, Somatostatin; RWM8CCW8GP / Octreotide
  • [Other-IDs] NLM/ PMC2730344
  •  go-up   go-down


32. Drake WM, Berney DM, Kovacs K, Monson JP: Markers of cell proliferation in a GH-producing adenoma of a patient treated with pegvisomant. Eur J Endocrinol; 2005 Aug;153(2):203-5
MedlinePlus Health Information. consumer health - Pituitary Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Markers of cell proliferation in a GH-producing adenoma of a patient treated with pegvisomant.
  • We report our findings on markers of cell proliferation (Ki-67 labelling index and topoisomerase-alpha expression) in a somatotroph pituitary tumour before and after exposure to pegvisomant, a GH receptor antagonist developed for the treatment of acromegaly.
  • Specimens from two separate pituitary operations, separated by a period of 17 years that included 4 years of pegvisomant treatment, were stained for markers of cellular proliferation.
  • Ki-67 labelling index and topoisomerase-alpha expression were both markedly greater (1-3% compared with 0-0.5% and 15-80% compared with 2-10% respectively) in the pegvisomant-exposed tumour compared with the earlier specimen.
  • Clearly, caution must be exercised when interpreting findings from a single case, particularly one sufficiently refractory to conventional therapies to require treatment with pegvisomant.
  • However, our data reinforce the requirement for careful radiological surveillance of the pituitary in the context of a drug that does not target the tumour responsible and where serum GH cannot serve as a marker of disease activity or tumour size.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16061824.001).
  • [ISSN] 0804-4643
  • [Journal-full-title] European journal of endocrinology
  • [ISO-abbreviation] Eur. J. Endocrinol.
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / DNA-Binding Proteins; 0 / Ki-67 Antigen; 0 / Receptors, Somatotropin; 0 / pegvisomant; 12629-01-5 / Human Growth Hormone; EC 5.99.1.3 / DNA Topoisomerases, Type II; EC 5.99.1.3 / DNA topoisomerase II alpha
  •  go-up   go-down


33. Lee EJ, Jameson JL: Cell-specific Cre-mediated activation of the diphtheria toxin gene in pituitary tumor cells: potential for cytotoxic gene therapy. Hum Gene Ther; 2002 Mar 1;13(4):533-42
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cell-specific Cre-mediated activation of the diphtheria toxin gene in pituitary tumor cells: potential for cytotoxic gene therapy.
  • Diphtheria toxin has been suggested for the treatment of malignant cancer.
  • In this paper, we describe a strategy for targeting the expression of the diphtheria toxin gene to growth hormone (GH)-producing pituitary tumor cells using adenoviral vectors.
  • We generated adenoviral vectors in which a stuffer DNA fragment, flanked by two loxP sequences, was placed between the GH or cytomegalovirus (CMV) promoters and the diphtheria toxin gene (GH-loxP-DT, and CMV-loxP-DT) or the beta-Gal gene (GH-loxP-Gal, and CMV-loxP-Gal).
  • Co-infection of GH-loxP-DT with either CMV-Cre or GH-Cre induced cytotoxicity that was limited to GH4 cells.
  • Intratumoral co-injection of adenoviruses carrying diphtheria toxin (GH-loxP-DT, and CMV-loxP-DT) and Cre recombinase (GH-Cre, and CMV-Cre) caused rapid regression of the transplanted GH4 tumors.
  • These results indicate that Cre-mediated activation of a loxP-repressed form of the DT gene provides a useful strategy for targeted suicide gene therapy.
  • This approach may be useful for GH-secreting adenomas and should be applicable to other neoplastic disorders.
  • [MeSH-major] Diphtheria Toxin / genetics. Integrases / genetics. Pituitary Neoplasms / genetics. Viral Proteins / genetics
  • [MeSH-minor] Adenoviridae. Animals. Cell Death / genetics. Gene Expression Regulation, Neoplastic. Gene Transfer Techniques. Genetic Therapy. Genetic Vectors. Growth Hormone / biosynthesis. Growth Hormone / genetics. Mice. Mice, Nude. Mice, Transgenic. Promoter Regions, Genetic. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11874631.001).
  • [ISSN] 1043-0342
  • [Journal-full-title] Human gene therapy
  • [ISO-abbreviation] Hum. Gene Ther.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Diphtheria Toxin; 0 / Viral Proteins; 9002-72-6 / Growth Hormone; EC 2.7.7.- / Cre recombinase; EC 2.7.7.- / Integrases
  •  go-up   go-down


34. Pisarek H, Pawlikowski M, Kunert-Radek J, Winczyk K: Does the response of GH-secreting pituitary adenomas to octreotide depend on the cellular localization of the somatostatin receptor subtypes SSTR2 and SSTR5? Endokrynol Pol; 2010 Mar-Apr;61(2):178-81
MedlinePlus Health Information. consumer health - Pituitary Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Does the response of GH-secreting pituitary adenomas to octreotide depend on the cellular localization of the somatostatin receptor subtypes SSTR2 and SSTR5?
  • INTRODUCTION: The immunohistochemical examination of somatostatin receptor (SSTR) subtypes expression in different endocrine tumours, including pituitary adenomas, revealed membranous or cytoplasmic distribution of SSTR1-5.
  • In an earlier study a positive correlation between the summarized score of SSTR2A + SSTR2B expressions and growth hormone (GH) response to octreotide administration was found, independently of receptor distribution within the cell.
  • The pituitary adenomas from these patients were immunostained to determine the hormonal phenotype and expression of SSTR subtypes.
  • The cytoplasmic but not the membranous localization is connected with the higher responsiveness to the octreotide in somatotropinomas.
  • [MeSH-major] Adenoma / drug therapy. Adenoma / pathology. Octreotide / pharmacology. Pituitary Neoplasms / drug therapy. Pituitary Neoplasms / pathology. Receptors, Somatostatin / analysis
  • [MeSH-minor] Adult. Aged. Antineoplastic Agents, Hormonal / pharmacology. Chemotherapy, Adjuvant. Cytoplasm / pathology. Female. Growth Hormone / secretion. Humans. Immunohistochemistry. Male. Middle Aged. Tissue Distribution

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20464704.001).
  • [ISSN] 0423-104X
  • [Journal-full-title] Endokrynologia Polska
  • [ISO-abbreviation] Endokrynol Pol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Receptors, Somatostatin; 0 / somatostatin receptor 2; 0 / somatostatin receptor 5; 9002-72-6 / Growth Hormone; RWM8CCW8GP / Octreotide
  •  go-up   go-down


35. Taboada GF, Luque RM, Neto LV, Machado Ede O, Sbaffi BC, Domingues RC, Marcondes JB, Chimelli LM, Fontes R, Niemeyer P, de Carvalho DP, Kineman RD, Gadelha MR: Quantitative analysis of somatostatin receptor subtypes (1-5) gene expression levels in somatotropinomas and correlation to in vivo hormonal and tumor volume responses to treatment with octreotide LAR. Eur J Endocrinol; 2008 Mar;158(3):295-303
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Quantitative analysis of somatostatin receptor subtypes (1-5) gene expression levels in somatotropinomas and correlation to in vivo hormonal and tumor volume responses to treatment with octreotide LAR.
  • OBJECTIVE: To determine whether the somatostatin receptor subtype (SSTR) expression profile correlates with hormonal and tumor volume responses to postsurgical octreotide long acting repeatable (OCT LAR) treatment.
  • DESIGN AND METHODS: Quantitative real-time RT-PCR was used to evaluate the absolute mRNA copy numbers for all five SSTR subtypes in 22 somatotropinomas.
  • Response to OCT LAR was studied by hormone levels (GH and IGF-I) and tumor volume (sella turcica magnetic resonance imaging).
  • A positive correlation was also found between SSTR2 mRNA levels and the percentage decrease in tumor volume after 6 months of OCT LAR (r=0.79, P=0.002, n=12).
  • CONCLUSIONS: Somatostatin receptor subtype 2 mRNA expression levels in somatotropinomas correlate positively with in vivo hormonal and tumor volume responses to OCT LAR.

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18299461.001).
  • [ISSN] 1479-683X
  • [Journal-full-title] European journal of endocrinology
  • [ISO-abbreviation] Eur. J. Endocrinol.
  • [Language] ENG
  • [Grant] United States / PHS HHS / / NIDDK 30677
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Membrane Proteins; 0 / RNA, Messenger; 0 / Receptors, Somatostatin; 0 / somatostatin receptor 2; 0 / somatostatin receptor 3; 0 / somatostatin receptor 5; 0 / somatostatin receptor subtype-4; 0 / somatostatin receptor type 1; 9002-72-6 / Growth Hormone; RWM8CCW8GP / Octreotide
  •  go-up   go-down


36. Zieliński G, Podgórski JK, Koziarski A, Warczyńska A, Zgliczyński W, Makowska A: [Surgical treatment of invasive pituitary adenomas (somatotropinoma or corticotropinoma)]. Neurol Neurochir Pol; 2003 Nov-Dec;37(6):1239-55
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Surgical treatment of invasive pituitary adenomas (somatotropinoma or corticotropinoma)].
  • [Transliterated title] Leczenie operacyjne czynnych hormonalnie (wydzielajacych GH lub ACTH) inwazyjnych gruczolaków przysadki mózgowej.
  • AIM OF THE STUDY: To evaluate efficiency of the transcranial epidural approach in the treatment of invasive GH- or ACTH-secreting pituitary adenomas with extension to the cavernous sinus.
  • MATERIAL AND METHODS: During the past two years (from January 2000 to December 2001) 14 patients with invasive GH- or ACTH-secreting pituitary adenomas extending to the cavernous sinus were operated on using the transcranial epidural approach.
  • Our experience is based on an analysis of 12 patients with GH-secreting tumors and 2 patients with ACTH-secreting adenomas.
  • Parasellar extension of the tumor was measured using the Knosp scale--in all the cases there was an extension to the cavernous sinus, in stage III (4 patients) or stage IV (10 patients).
  • RESULTS: In none of the cases a total surgical removal of the invasive GH-secreting adenoma was attained (according the following cure criteria: basal serum GH level below 2.5 micrograms/l, OGTT < 1 microgram/l, normal sex- and age-related IGF-I level).
  • There was no deterioration of pituitary function and no cases of diabetes insipidus in our group.
  • CONCLUSION: Transcranial epidural approach is an alternative to radiotherapy and/or prolonged medication in the treatment of invasive GH- or ACTH-secreting pituitary adenomas.
  • [MeSH-major] Adenoma / surgery. Adrenocorticotropic Hormone / secretion. Growth Hormone / secretion. Neurosurgical Procedures / methods. Pituitary Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Cavernous Sinus / pathology. Female. Humans. Hypophysectomy / methods. Male. Middle Aged. Neoplasm Invasiveness. Retrospective Studies. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • Hazardous Substances Data Bank. Corticotropin .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15174237.001).
  • [ISSN] 0028-3843
  • [Journal-full-title] Neurologia i neurochirurgia polska
  • [ISO-abbreviation] Neurol. Neurochir. Pol.
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 9002-60-2 / Adrenocorticotropic Hormone; 9002-72-6 / Growth Hormone
  •  go-up   go-down


37. Miyoshi T, Otsuka F, Otani H, Inagaki K, Goto J, Yamashita M, Ogura T, Iwasaki Y, Makino H: Involvement of bone morphogenetic protein-4 in GH regulation by octreotide and bromocriptine in rat pituitary GH3 cells. J Endocrinol; 2008 Apr;197(1):159-69

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Involvement of bone morphogenetic protein-4 in GH regulation by octreotide and bromocriptine in rat pituitary GH3 cells.
  • Here we investigated roles of the pituitary bone morphogenetic protein (BMP) system in modulating GH production regulated by a somatostatin analog, octreotide (OCT) and a dopamine agonist, bromocriptine (BRC) in rat pituitary somatolactotrope tumor GH3 cells.
  • The GH3 cells were found to express BMP ligands, including BMP-4 and BMP-6; BMP type-1 and type-2 receptors (except the type-1 receptor, activin receptor-like kinase (ALK)-6); and Smad signaling molecules.
  • Individual treatment with OCT and BRC reduced forskolin-induced GH secretion.
  • These findings may explain the mechanism of resistance of GH reduction to a combination therapy with OCT and BRC for GH-producing pituitary adenomas.
  • [MeSH-major] Bone Morphogenetic Protein 4 / physiology. Bromocriptine / pharmacology. Growth Hormone / biosynthesis. Octreotide / pharmacology
  • [MeSH-minor] Animals. Bone Morphogenetic Protein 6 / genetics. Bone Morphogenetic Protein 6 / physiology. Bone Morphogenetic Protein Receptors / analysis. Bone Morphogenetic Protein Receptors / genetics. Cell Line, Tumor. Colforsin / pharmacology. Cyclic AMP / biosynthesis. Dose-Response Relationship, Drug. Rats. Receptors, Somatostatin / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18372242.001).
  • [ISSN] 1479-6805
  • [Journal-full-title] The Journal of endocrinology
  • [ISO-abbreviation] J. Endocrinol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Bmp6 protein, rat; 0 / Bone Morphogenetic Protein 4; 0 / Bone Morphogenetic Protein 6; 0 / Receptors, Somatostatin; 1F7A44V6OU / Colforsin; 3A64E3G5ZO / Bromocriptine; 9002-72-6 / Growth Hormone; E0399OZS9N / Cyclic AMP; EC 2.7.11.30 / Bone Morphogenetic Protein Receptors; RWM8CCW8GP / Octreotide
  •  go-up   go-down


38. Gola M, Doga M, Bonadonna S, Mazziotti G, Vescovi PP, Giustina A: Neuroendocrine tumors secreting growth hormone-releasing hormone: Pathophysiological and clinical aspects. Pituitary; 2006;9(3):221-9
MedlinePlus Health Information. consumer health - Carcinoid Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neuroendocrine tumors secreting growth hormone-releasing hormone: Pathophysiological and clinical aspects.
  • Hypothalamic GHRH is secreted into the portal system, binds to specific surface receptors of the somatotroph cell and elicits intracellular signals that modulate pituitary GH synthesis and/or secretion.
  • Moreover, GHRH is synthesized and expressed in multiple extrapituitary tissues.
  • Excessive peripheral production of GHRH by a tumor source would therefore be expected to cause somatotroph cell hyperstimulation, increased GH secretion and eventually pituitary acromegaly.
  • The distinction of pituitary vs. extrapituitary acromegaly is extremely important in planning effective management.
  • Dynamic pituitary tests are not helpful in distinguishing acromegalic patients with pituitary tumors from those harbouring extrapituitary tumors.
  • Plasma GHRH levels are usually elevated in patients with peripheral GHRH-secreting tumors, and are normal or low in patients with pituitary acromegaly.
  • Unique and unexpected clinical features in an acromegalic patient, including respiratory wheezing or dyspnea, facial flushing, peptic ulcers, or renal stones sometimes are helpful in alerting the physician to diagnosing non pituitary endocrine tumors.
  • If no facility to measure plasma GHRH is available, and in the absence of MRI evidence of pituitary adenoma, a CT scan of the thorax and abdominal ultrasound could be performed to exclude with good approximation the possibility of an ectopic GHRH syndrome.
  • Surgical resection of the tumor secreting ectopic GHRH should be the logical approach to a patient with ectopic GHRH syndrome.
  • Standard chemotherapy directed at GHRH-producing carcinoid tumors is generally unsuccessful in controlling the activated GH axis.
  • In fact, long-acting somatostatin analogs may be able to control not only the ectopic hormonal secretion syndrome, but also, in some instances, tumor growth.
  • Therefore, although cytotoxic chemotherapy, pituitary surgery, or irradiation still remain available therapeutic options, long-acting somatostatin analogs are now preferred as a second-line therapy in patients with carcinoid tumors and ectopic GHRH-syndrome.
  • [MeSH-major] Acromegaly / etiology. Adenoma / secretion. Carcinoid Tumor / secretion. Growth Hormone-Releasing Hormone / secretion. Growth Hormone-Secreting Pituitary Adenoma / secretion. Neuroendocrine Tumors / secretion. Paraneoplastic Endocrine Syndromes / etiology
  • [MeSH-minor] Animals. Biomarkers, Tumor / blood. Diagnosis, Differential. Human Growth Hormone / blood. Humans. Insulin-Like Growth Factor I / metabolism. Treatment Outcome. Up-Regulation

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Endocrinol Metab Clin North Am. 1992 Sep;21(3):539-51 [1521511.001]
  • [Cites] Endocrinology. 1997 Nov;138(11):4543-51 [9348176.001]
  • [Cites] Eur J Endocrinol. 2005 Dec;153(6):737-40 [16322377.001]
  • [Cites] Semin Oncol. 1987 Sep;14(3):343-53 [2820064.001]
  • [Cites] Biochem Biophys Res Commun. 1982 Nov 16;109(1):152-8 [7159418.001]
  • [Cites] Endocrinology. 1985 Aug;117(2):457-67 [2862007.001]
  • [Cites] Endocr J. 1993 Feb;40(1):133-9 [7951487.001]
  • [Cites] J Endocrinol Invest. 1993 Sep;16(8):585-90 [8258646.001]
  • [Cites] Nature. 1983 Feb 17-23;301(5901):607-8 [6402707.001]
  • [Cites] Endocr Rev. 1998 Dec;19(6):717-97 [9861545.001]
  • [Cites] Endocr Rev. 1988 Aug;9(3):357-73 [3145190.001]
  • [Cites] Metabolism. 1991 May;40(5):519-23 [2023538.001]
  • [Cites] Domest Anim Endocrinol. 1997 Sep;14(5):358-66 [9347256.001]
  • [Cites] J Neurosci. 1996 Dec 15;16(24):8140-8 [8987839.001]
  • [Cites] J Endocrinol Invest. 2003 Feb;26(2):163-9 [12739745.001]
  • [Cites] Nature. 1983 Jun 9-15;303(5917):532-5 [6406907.001]
  • [Cites] J Clin Endocrinol Metab. 1984 May;58(5):796-803 [6423659.001]
  • [Cites] J Clin Endocrinol Metab. 1989 May;68(5):917-24 [2565913.001]
  • [Cites] Proc Soc Exp Biol Med. 1990 Mar;193(3):232-5 [2106141.001]
  • [Cites] Neurosurgery. 2002 Jun;50(6):1356-9; discussion 1360 [12015856.001]
  • [Cites] J Neuroendocrinol. 1989 Apr 1;1(2):109-15 [19210467.001]
  • [Cites] Endocrinology. 1976 Mar;98(3):580-9 [177264.001]
  • [Cites] Clin Endocrinol (Oxf). 2001 Mar;54(3):301-7 [11298081.001]
  • [Cites] Neuroendocrinology. 1990 May;51(5):572-5 [1693757.001]
  • [Cites] J Clin Endocrinol Metab. 1995 Nov;80(11):3321-6 [7593445.001]
  • [Cites] Metabolism. 1990 Sep;39(9 Suppl 2):40-2 [1976218.001]
  • [Cites] N Engl J Med. 1990 Aug 2;323(5):322-7 [2164153.001]
  • [Cites] Endocrinology. 1984 Nov;115(5):2032-4 [6436012.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Jun;88(6):2797-802 [12788890.001]
  • [Cites] J Clin Endocrinol Metab. 1984 Aug;59(2):197-201 [6330151.001]
  • [Cites] J Clin Endocrinol Metab. 2005 Apr;90(4):2104-9 [15671091.001]
  • [Cites] J Clin Endocrinol Metab. 1997 Apr;82(4):1210-9 [9100598.001]
  • [Cites] Endocrinology. 1993 Sep;133(3):1029-34 [8103446.001]
  • [Cites] Pharmacol Res. 1996 Nov-Dec;34(5-6):247-68 [9076850.001]
  • [Cites] J Clin Endocrinol Metab. 1984 Nov;59(5):846-9 [6434585.001]
  • [Cites] Cancer. 1988 Jan 15;61(2):221-6 [2891432.001]
  • [Cites] Metabolism. 1992 Dec;41(12):1291-4 [1281259.001]
  • [Cites] Ann Oncol. 2001;12 Suppl 2:S89-94 [11762359.001]
  • [Cites] Endocrinol Jpn. 1989 Apr;36(2):229-36 [2550207.001]
  • [Cites] J Clin Endocrinol Metab. 1989 Jan;68(1):180-5 [2491860.001]
  • [Cites] J Clin Invest. 1980 Jan;65(1):43-54 [6243140.001]
  • [Cites] Physiol Rev. 1999 Apr;79(2):511-607 [10221989.001]
  • [Cites] J Clin Endocrinol Metab. 1989 Jan;68(1):22-8 [2491864.001]
  • [Cites] Clin Endocrinol (Oxf). 1987 Sep;27(3):297-306 [2892599.001]
  • [Cites] FEBS Lett. 1996 Sep 23;394(1):1-4 [8925914.001]
  • [Cites] J Clin Endocrinol Metab. 1987 Mar;64(3):585-91 [3102543.001]
  • [Cites] Endocrinology. 1985 Jul;117(1):424-6 [2988927.001]
  • [Cites] J Endocrinol Invest. 2003;26(8 Suppl):4-7 [15233203.001]
  • [Cites] Nature. 1982 Nov 18;300(5889):276-8 [6292724.001]
  • [Cites] J Clin Invest. 1990 Jul;86(1):17-24 [1973173.001]
  • [Cites] Endocrinology. 1972 Oct;91(4):1071-8 [5051331.001]
  • [Cites] J Endocrinol Invest. 2003 Dec;26(12):1242-7 [15055479.001]
  • [Cites] J Endocrinol Invest. 2005;28(11 Suppl International):43-7 [16625844.001]
  • [Cites] J Clin Invest. 1982 Nov;70(5):965-77 [6290540.001]
  • [Cites] Endocr Rev. 1991 Nov;12(4):450-82 [1684746.001]
  • [Cites] Endocrinology. 1984 Apr;114(4):1082-5 [6423368.001]
  • [Cites] Endocrinology. 1992 Mar;130(3):1097-102 [1537276.001]
  • [Cites] Clin Endocrinol (Oxf). 1986 Feb;24(2):135-40 [2871948.001]
  • [Cites] Nature. 1983 Nov 3-9;306(5938):84-5 [6415487.001]
  • [Cites] J Clin Endocrinol Metab. 2000 Feb;85(2):526-9 [10690849.001]
  • [Cites] Nature. 1985 Mar 21-27;314(6008):279-81 [2858817.001]
  • [Cites] Endocrinology. 1985 Oct;117(4):1598-601 [3928335.001]
  • [Cites] Lancet. 1984 Aug 18;2(8399):401-2 [6147476.001]
  • [Cites] J Clin Endocrinol Metab. 1998 Sep;83(9):3104-9 [9745411.001]
  • [Cites] Endocrinology. 1983 Nov;113(5):1726-31 [6194979.001]
  • [Cites] Nature. 1993 Jul 15;364(6434):208-13 [8391647.001]
  • [Cites] Eur J Endocrinol. 1995 Jan;132(1):12-24 [7850005.001]
  • [Cites] Am J Clin Pathol. 1986 Jan;85(1):13-20 [3000164.001]
  • [Cites] Eur J Endocrinol. 1998 Jul;139(1):59-71 [9703380.001]
  • [Cites] Clin Endocrinol (Oxf). 1976 Sep;5(5):503-13 [991433.001]
  • [Cites] J Clin Endocrinol Metab. 2002 Sep;87(9):4054-8 [12213843.001]
  • [Cites] Science. 1982 Nov 5;218(4572):585-7 [6812220.001]
  • [Cites] Clin Endocrinol (Oxf). 1989 Apr;30(4):367-77 [2574645.001]
  • [Cites] Endocrinology. 1996 Apr;137(4):1326-31 [8625907.001]
  • [Cites] Endocr Rev. 1986 Aug;7(3):223-53 [2874984.001]
  • [Cites] Am J Med. 1984 Apr;76(4):605-16 [6424465.001]
  • [Cites] Science. 1975 Feb 7;187(4175):447-9 [1111113.001]
  • [Cites] J Clin Endocrinol Metab. 1985 Feb;60(2):370-5 [3917460.001]
  • [Cites] Cancer. 1991 May 15;67(10):2538-42 [2015554.001]
  • [Cites] J Thorac Cardiovasc Surg. 2004 Oct;128(4):631-2 [15457172.001]
  • [Cites] Endocrinol Metab Clin North Am. 1992 Sep;21(3):575-95 [1521513.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Aug;86(8):3989-95 [11502843.001]
  • [Cites] J Clin Endocrinol Metab. 1989 Feb;68(2):499-504 [2493033.001]
  • [Cites] Adv Tech Stand Neurosurg. 1995;22:3-53 [7495421.001]
  • [Cites] J Clin Endocrinol Metab. 1984 Oct;59(4):747-51 [6434578.001]
  • [Cites] Annu Rev Med. 1990;41:447-55 [2184742.001]
  • [Cites] J Endocrinol Invest. 1993 Jan;16(1):69-81 [8445159.001]
  • [Cites] Br Med J (Clin Res Ed). 1986 Apr 12;292(6526):981-2 [2870758.001]
  • [Cites] J Clin Endocrinol Metab. 1984 Jan;58(1):212-4 [6417155.001]
  • [Cites] Science. 1985 Oct 25;230(4724):461-3 [2864742.001]
  • [Cites] Mol Endocrinol. 1992 Oct;6(10):1734-44 [1333056.001]
  • [Cites] Eur J Endocrinol. 1997 Jun;136(6):553-65 [9225715.001]
  • [Cites] Ir J Med Sci. 2004 Oct-Dec;173(4):215-6 [16323617.001]
  • [Cites] Acta Endocrinol (Copenh). 1985 May;109(1):13-8 [3923754.001]
  • [Cites] Endocrinology. 1991 Feb;128(2):1151-8 [1671214.001]
  • [Cites] J Endocrinol Invest. 1994 Oct;17(9):717-22 [7868816.001]
  • [Cites] Brain Res. 1989 Feb 27;481(1):8-15 [2565134.001]
  • [Cites] Eur J Endocrinol. 1995 Sep;133(3):320-4 [7581949.001]
  • [Cites] Endocrinology. 1985 Apr;116(4):1334-40 [3918850.001]
  • (PMID = 17036195.001).
  • [ISSN] 1573-7403
  • [Journal-full-title] Pituitary
  • [ISO-abbreviation] Pituitary
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 12629-01-5 / Human Growth Hormone; 67763-96-6 / Insulin-Like Growth Factor I; 9034-39-3 / Growth Hormone-Releasing Hormone
  • [Number-of-references] 101
  •  go-up   go-down


39. Gołkowski F, Buziak-Bereza M, Huszno B: [Evaluation of the efficacy of long-acting somatostatin analog as adjunctive therapy in patients with active acromegaly]. Przegl Lek; 2006;63(3):117-22
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Evaluation of the efficacy of long-acting somatostatin analog as adjunctive therapy in patients with active acromegaly].
  • Transsphenoidal surgery is the first-line therapy for patients with acromegaly, but can achieve biochemical control with normalization of somatomedin C in 40-80% of cases.
  • All patients with continued growth hormone hypersecretion after neurosurgery require adjunctive therapy to prevent morbidity and premature mortality.
  • The aim of our study was to evaluate the efficacy of long-acting somatostatin analog--octreotide LAR (OCT-LAR) as adjunctive therapy for patients with persistent disease.
  • All patients were diagnosed as having growth hormone secreting pituitary tumor and underwent transsphenoidal surgery (TSS).
  • Radiotherapy (RT) was used as adjunctive therapy in 7 of investigated persons.
  • In all subjects elevated level of somatomedin C was found, 9 have increased level of growth hormone (hGH) as well.
  • After 6 months therapy with OCT-LAR we noticed drop in somatomedin C and hGH levels in all patients.
  • We found no significant correlation between decrease in somatomedin C and its level prior to the treatment (p=0.8), but high positive correlation between decrease in hGh level and its initial value (R=0.75, p=0.002).
  • The therapeutic outcome defined as decrease in somatomedin C level was not significantly different between patients with or without adjunctive radiotherapy in the past (p=0.08) and between patients with intensive or weak isotope collection in the pituitary in 99mTc-octreotide scintiscan (p=0.2).
  • Initial values of somatomedin C as well as age and isotopic imaging findings are not valuable predictor factors for therapeutic outcome.
  • [MeSH-major] Acromegaly / drug therapy. Adenoma / drug therapy. Antineoplastic Agents, Hormonal / administration & dosage. Octreotide / administration & dosage. Pituitary Neoplasms / drug therapy
  • [MeSH-minor] Adult. Female. Follow-Up Studies. Growth Hormone / secretion. Humans. Insulin-Like Growth Factor I / secretion. Male. Middle Aged. Treatment Outcome

  • Genetic Alliance. consumer health - Acromegaly.
  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16967698.001).
  • [ISSN] 0033-2240
  • [Journal-full-title] Przegla̧d lekarski
  • [ISO-abbreviation] Prz. Lek.
  • [Language] pol
  • [Publication-type] Clinical Trial; English Abstract; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 67763-96-6 / Insulin-Like Growth Factor I; 9002-72-6 / Growth Hormone; RWM8CCW8GP / Octreotide
  •  go-up   go-down






Advertisement